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Summary
Background—In transitioning from the Millennium Development Goal to the Sustainable 
Development Goal era, it is imperative to comprehensively assess progress toward reducing 
maternal mortality to identify areas of success, remaining challenges, and frame policy 
discussions. We aimed to quantify maternal mortality throughout the world by underlying cause 
and age from 1990 to 2015.
Methods—We estimated maternal mortality at the global, regional, and national levels from 1990 
to 2015 for ages 10–54 years by systematically compiling and processing all available data sources 
from 186 of 195 countries and territories, 11 of which were analysed at the subnational level. We 
quantified eight underlying causes of maternal death and four timing categories, improving 
estimation methods since GBD 2013 for adult all-cause mortality, HIV-related maternal mortality, 
and late maternal death. Secondary analyses then allowed systematic examination of drivers of 
trends, including the relation between maternal mortality and coverage of specific reproductive 
health-care services as well as assessment of observed versus expected maternal mortality as a 
function of Socio-demographic Index (SDI), a summary indicator derived from measures of 
income per capita, educational attainment, and fertility.
Findings—Only ten countries achieved MDG 5, but 122 of 195 countries have already met SDG 
3.1. Geographical disparities widened between 1990 and 2015 and, in 2015, 24 countries still had 
a maternal mortality ratio greater than 400. The proportion of all maternal deaths occurring in the 
bottom two SDI quintiles, where haemorrhage is the dominant cause of maternal death, increased 
from roughly 68% in 1990 to more than 80% in 2015. The middle SDI quintile improved the most 
from 1990 to 2015, but also has the most complicated causal profile. Maternal mortality in the 
highest SDI quintile is mostly due to other direct maternal disorders, indirect maternal disorders, 
and abortion, ectopic pregnancy, and/or miscarriage. Historical patterns suggest achievement of 
SDG 3.1 will require 91% coverage of one antenatal care visit, 78% of four antenatal care visits, 
81% of in-facility delivery, and 87% of skilled birth attendance.
Interpretation—Several challenges to improving reproductive health lie ahead in the SDG era. 
Countries should establish or renew systems for collection and timely dissemination of health 
data; expand coverage and improve quality of family planning services, including access to 
contraception and safe abortion to address high adolescent fertility; invest in improving health 
system capacity, including coverage of routine reproductive health care and of more advanced 
obstetric care—including EmOC; adapt health systems and data collection systems to monitor and 
reverse the increase in indirect, other direct, and late maternal deaths, especially in high SDI 
locations; and examine their own performance with respect to their SDI level, using that 
information to formulate strategies to improve performance and ensure optimum reproductive 
health of their population.
Funding—Bill & Melinda Gates Foundation.
Introduction
The global community adopted a set of 17 Sustainable Development Goals (SDGs) on Sept 
25, 2015, to provide benchmark targets for global development between 2015 and 2030.1 
These goals are intended to build on the momentum and enthusiasm generated by the 
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Millennium Development Goals (MDGs),2 but also to reframe them within the context of a 
myriad of environmental and societal challenges inherent in achieving sustainable global 
development,3,4 The Global Strategy for Women’s, Children’s, and Adolescents’ Health 
2016–2030 further aims to position the global discussion of maternal mortality within a 
continuum of programmes aimed at improving the health of women and children globally.5
As the MDG era has now come to a close and the SDG era is beginning, it is imperative to 
provide a comprehensive account of global, regional, and national progress toward MDG 5. 
Such information is of crucial importance to identify areas of success and remaining 
challenges, and to help to frame policy discussions as we continue to prioritise maternal and 
reproductive health for women in the SDG era.6 Whereas MDG 5 set a target reduction of 
75% in the maternal mortality ratio (MMR; number of maternal deaths per 100 000 
livebirths) between 1990 and 2015, SDG 3.1 sets a specific target for all countries to lower 
MMR to less than 70 by 2030. A secondary target of MDG 5, adopted in 2005, called for 
universal access to reproductive health care with named subtargets for contraceptive 
prevalence, adolescent pregnancy, antenatal care coverage, and family planning services,7 
but notably not for other reproductive health services such as skilled birth attendance, in-
facility delivery, or EmOC services. Because of the late addition of reproductive health 
access to the MDG agenda, related data collection systems have taken time to mature and 
this issue has not been tracked as closely as maternal mortality. SDG 3.7 has continued the 
calls for universal access to sexual and reproductive health services by 2030.
We have completed this study as part of the Global Burden of Disease (GBD) 2015, with the 
specific objective of ascertaining levels and trends in maternal mortality over the entire 
MDG period at the national, regional, and global levels. Relatedly, by also examining 
maternal mortality trends by age, cause, geography, and timing of death, we seek to better 
understand trends in maternal mortality epidemiology and thus generate insight into drivers 
of progress—or lack thereof—toward achievement of MDG 5 and help to frame discussions 
for monitoring of SDG 3.1 and 3.7. Multiple previous analyses, including several completed 
as part of the GBD collaboration have sought to provide the best possible information about 
levels and trends in maternal mortality.8–14 In dual recognition of both the importance and 
difficulty of accurately reporting on maternal mortality in many settings,15,16 each has 
incorporated increasingly large and geographically precise datasets and used more advanced 
statistical models. In their latest iteration,12 the WHO methods have also now adopted a 
single model for all countries and computed statistical uncertainty intervals. Important 
differences remain, however, between WHO and GBD maternal mortality estimates that at 
times paint divergent pictures of levels and trends in maternal mortality globally and in 
many countries. The main differences now stem from data selection, quality appraisal, data 
processing, and adult mortality estimation rather than the statistical maternal mortality 
models themselves.
In this GBD 2015 report, we present the underlying data for 519 distinct geographical units 
in 195 countries and territories, our methods for processing those data, the subsequent 
analytical approach, and findings on maternal mortality from 1990 to 2015. GBD 2010, 
published in 2012, presented results for 187 countries with a population greater than 50 000 
in the year 2000.17 Collaborative teams completed subnational assessments for the UK, 
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Mexico, and China for GBD 2013, expanding the number of geographies in the GBD 
analysis to 296.18–21 The value of subnational assessments to local decision makers22 has 
led to expansion of subnational analyses in GBD 2015 to also include Brazil, India, Japan, 
Kenya, Saudi Arabia, South Africa, Sweden, and the USA. We expect subnational analyses 
for other countries will be added in future GBD iterations. The expansion of the 
geographical units in the GBD will continue in a way that will sustain comparability over 
time for the period 1990 to present and across all geographical entities. We have not 
included constant rate-of-change forecasts in this Article because, as part of the broader 
effort to quantify the population disease burden, we are developing a set of rigorous 
statistical models to forecast each component of the GBD—including maternal mortality—
and we expect to be able to explore much more robust forecasts in the near future.
As with all GBD revisions, the GBD 2015 study describes updated maternal mortality 
estimates for the entire time series from 1990 to 2015 based on newly identified data sources 
released or collected since GBD 2013. In response to published commentaries and 
unpublished seminars and communications on GBD methods, various methodological 
refinements have been implemented.23,24 In addition, a major effort toward data and code 
transparency has been part of the GBD 2015 cycle. And as with each GBD cycle, the full 
time series published here supersedes previous GBD studies. This analysis explores global, 
regional, national, and subnational progress and seeks to identify correlates that help to 
explain why some nations have seen great improvements in maternal health, while others 
have stagnated and others still have worsened. These include examination of associations in 
national maternal mortality levels and trends with coverage of reproductive health 
interventions and Socio-demographic Index (SDI).
Methods
Overview
Maternal mortality is defined as a death that occurs to a woman as a direct result of obstetric 
complications or indirectly as a result of pregnancy-induced exacerbation of pre-existing 
medical conditions, but not as a result of incidental or accidental causes. To ensure internal 
consistency with all other causes of death, maternal mortality was also again analysed as a 
component of the overall GBD study. Many of the analytical components are therefore 
shared with other causes, including methods of data source identification and cataloguing, 
data preparation, modelling platforms, and processing of results. Here, we will focus on 
parts of the process that are unique, have been updated since GBD 2013, or are especially 
relevant to our analysis of maternal mortality. Figure 1 illustrates details of the analysis. 
General components are described in the appendix (pp 2–54), in other GBD 2015 Articles in 
The Lancet, and have also been published previously.10,20,25 This report follows the 
Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER) guidelines, 
which recommends documentation of data sources, methods, and analysis.26
Maternal mortality estimation
Geographical units of analysis—Our analysis was completed separately for 519 unique 
locations in 195 countries and territories, including all 188 countries analysed in GBD 2013 
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as well as seven additional countries or territories—namely, American Samoa, Bermuda, 
Greenland, Guam, Northern Mariana Islands, Puerto Rico, and the Virgin Islands, where 
high-quality vital registration data were available. Of note, these territories were not 
included in the national totals for Denmark, the UK, or the USA, but were instead included 
in GBD 2013 regional totals. All 195 countries are hierarchically organised into 21 regions, 
each of which is nested in one of seven super regions. Based on a combination of data 
availability and collaborator interest, we disaggregated GBD 2015 analyses into subnational 
units for several countries, including 26 states and one district for Brazil, 34 provinces and 
municipalities for China, 31 states and union territory groupings for India that include 62 
rural and urban units, 47 prefectures for Japan, 47 counties for Kenya, 32 states and districts 
for Mexico, 13 provinces for Saudi Arabia, nine provinces for South Africa, two regions for 
Sweden, 13 regions for the UK (Northern Ireland, Scotland, Wales, England, and nine 
subregions of England), and 51 states and districts for the USA. At the first subnational unit 
level, we have a total of 256 geographical units. In this Article, we present results for 
countries and territories, regions, super regions, SDI quintiles, and at the global level.
Data input and processing
The contents of the dataset used in our final model are shown in the appendix (p 667) and 
are compared with those used by the recent WHO analysis.12 A map showing the data 
coverage by location for all source types combined is shown in the appendix (p 57). We had 
599 unique sources from data from 186 of 195 countries (95%), covering 12 052 site years, 
an increase of 71% from GBD 2013 when we had 7056 total site years of maternal mortality 
data. This compares to only 203 sources covering 2636 total site years in the WHO analysis. 
The nine countries without maternal mortality data included Andorra, Angola, Equatorial 
Guinea, the Federated States of Micronesia, Marshall Islands, Samoa, Solomon Islands, 
Somalia, and Vanuatu. Maternal mortality data were also available for additional subnational 
locations in Mexico, China, the UK, Japan, the USA, Kenya, South Africa, India, Sweden, 
and Brazil. All data were stored in a centralised structured query language causes-of-death 
database in three formats: number of deaths, cause-specific mortality rate per capita, and 
cause fraction (proportion of all deaths due to maternal causes).
Vital registration systems have been shown to underestimate maternal mortality, but the 
amount of underestimation varies by setting and can change over time.22–24 We therefore 
used a method that maximises the data-driven nature—and specificity—of our adjustments 
by systematically evaluating each underlying data source. We included all sources with 
population-level data for maternal mortality from each geography. We used a standardised 
process to identify, extract, and process all relevant data sources, including those from vital 
registration systems, verbal autopsy studies, maternal surveillance systems, national 
confidential enquiry reports, and sibling survival histories from health surveys and censuses 
(figure 1, step 1).
Standardised algorithms were implemented to adjust for age-specific, year-specific, and 
geography-specific patterns of incompleteness and underreporting for vital registration, as 
well as patterns of misclassification of deaths in vital registration and verbal autopsy sources 
(figure 1, step 2). These generalised algorithms were used across all GBD causes and thus 
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were able to capture trends in quality changes in vital registration with respect to maternal 
mortality, even in locations where surveillance studies have not been completed.20 Each 
code in International Classification of Diseases (ICD)-coded vital registration datasets was 
uniquely assigned to a corresponding cause in the hierarchical GBD cause list. Codes used 
in tabular classification systems (eg, ICD-9 basic tabular list, verbal autopsy, maternal 
surveillance systems) were likewise uniquely matched with a GBD cause. A proportion of 
deaths assigned to causes that cannot be underlying causes of death (garbage coded) were 
reassigned to maternal causes based on statistical redistribution packages, as described in the 
appendix (pp 2–18). The net effect of data processing steps on vital registration across all 
locations and years combined was to increase maternal deaths by 168%. The net effect 
varied by geography and year even among those countries and territories with at least 10 
years of data, ranging from less than 1% increase in Mongolia to a nine-fold increase in 
China. Final and raw vital registration data for each country and year are shown in the 
appendix (pp 519–652), including proportion of all deaths assigned to garbage codes, and 
comparisons with WHO vital registration adjustments.12 Figure 2 shows the results of 
garbage code redistribution for maternal mortality at the global level. Distinct cause 
groupings, many of which are garbage codes, are shown on the left and the relative thickness 
of lines shows the proportion of all deaths from those codes that were subsequently mapped 
to corresponding maternal causes on the right. Note that by definition the so-called non-
garbage codes on the left map directly to maternal causes.
In view of their inconsistent use by vital registration systems, codes pertaining to HIV-
related indirect maternal deaths were excluded at this stage in favour of a more 
comprehensive approach to estimate the effect of HIV on maternal death (see below for 
more details of HIV-related maternal mortality analysis). In addition to vital registration, we 
identified maternal mortality surveillance systems and published confidential enquiry studies 
identified via targeted web search and systematic review of national ministry of health 
websites. Confidential enquiries are specialised studies designed to investigate the number 
and circumstances of maternal deaths. Inclusion required a clear distinction identified 
between maternal and incidental deaths during pregnancy. As with vital registration systems, 
HIV-related indirect maternal deaths were excluded from surveillance datasets at this stage 
(see below for more details) but otherwise were unadjusted. Single-year sibling history and 
survey data derived from health surveys and censuses was processed as in GBD 2013, using 
Gakidou-King weights to adjust for survivor bias and only retaining data from older surveys 
when years of death overlapped (figure 1, step 3).27
Our general approach to quantify the role of HIV in maternal mortality is unchanged from 
GBD 2013 and again involved comprehensive estimation of the population attributable 
fraction of maternal mortality to HIV10 (figure 1, step 4). In view of the increased baseline 
mortality of those with advanced HIV, this approach has helped to distinguish between 
deaths in HIV-positive women that were caused by pregnancy and those for which the 
pregnancy was incidental to their death. A detailed description of the GBD 2013 approach 
and updates is in the appendix (pp 21–24). An updated systematic literature search 
completed on July 20, 2015, did not identify any new sources to inform either our meta-
analysis of relative risk of pregnancy-related death for HIV-positive versus HIV-negative 
women or our analysis on the proportion of pregnancy-related deaths in HIV-positive women 
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that are maternal (versus incidental). HIV prevalence in pregnancy, approximated as the ratio 
of livebirths in HIV-positive to HIV-negative women, was updated using our modified EPP-
Spectrum model. We also made two important improvements to overall HIV mortality 
estimation, both of which affected our HIV-related maternal mortality estimates. First, to 
improve the internal consistency of estimates developed for countries with generalised HIV 
epidemics, we modified EPP-Spectrum to improve how it integrates ART-dependent HIV 
progression and mortality data from published cohort studies and combined these findings 
with results derived from statistical examination of how all-cause mortality relates to crude 
HIV death rate. Second, in recognition of the fact that HIV mortality rivals or exceeds that of 
high mortality events (referred to as so-called fatal discontinuities in GBD 2015) such as war 
and natural disaster in many locations—and that such discontinuities have major detrimental 
effects on statistical mortality models—all of our maternal mortality data were processed to 
ensure incidental HIV deaths were excluded before modelling. We processed sibling history 
and census data to exclude incidental HIV deaths using population attributable fractions 
calculated above for each geography, age group, and year. This method is analogous to the 
HIV-correction process used in GBD 2013 except that the correction was done on the data 
itself rather than the preliminary model results. To ensure consistency between all data 
sources, we also applied population attributable fractions to all vital registration, verbal 
autopsy, and surveillance data to add back the corresponding number of HIV-related indirect 
maternal deaths in each of those sources. Finally, to reduce error introduced by large 
stochastic fluctuations and upward bias introduced by data that have a value of zero, we 
processed all data of all specifications using Bayesian noise-reduction algorithms (see 
appendix [pp 2–18] for more details; figure 1, step 5). Zeros are problematic because the log 
of zero is undefined, so all zeroes would otherwise be ignored by log-based statistical 
mortality models.
Modelling overall maternal mortality
We again modelled overall maternal mortality using cause-of-death ensemble modelling 
(CODEm), which was developed for GBD 201028 and is described in detail in the appendix 
(figure 1, step 6). CODEm runs four separate models, including natural log of age-specific 
death rates and logit-transformed cause-fractions in each of linear and spatiotemporal 
Gaussian process regression formats. Using multiple holdout patterns and cross-validation 
testing, every combination of covariates was tested. Models where regression coefficients 
met requirements for direction and significance were then ranked on the basis of out-of-
sample predictive validity performance through multiple iterations of cross-validation 
testing. We then generated a series of ensemble models with a range of weightings such that 
top-performing component models contributed the most to the final prediction. We ran two 
separate CODEm models, one for countries with extensive complete vital registration 
representation and another for all countries combined (see appendix pp 655–59 for a list of 
countries and territories with extensive complete vital registration included in separate 
CODEm model). The purpose was so that heterogeneous data from countries without 
extensive complete vital registration representation would not inflate the uncertainty interval 
(UI) for countries with extensive and complete cause-specific death data. Results from the 
former model were used for all geographies with extensive complete vital registration 
representation; results for all other geographies were from the latter model.
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Predictive covariates were specified with respect to required directionality and significance 
level of regression coefficients (see appendix [p 661] for full details). Three hierarchical 
covariate levels reduce the combinatorial burden on CODEm. Covariates with strong or 
causal association were assigned to level 1; those that are ecologically related were assigned 
to level 2; and those where association is suspected but not proven at the population level 
were assigned to level 3. We largely used the same covariates as in GBD 2013, including 
age-standardised fertility rate, total fertility rate, years of education per capita, lag-
distributed income (international $ per capita), neonatal mortality rate (per 1000 livebirths), 
HIV mortality in females of reproductive age, and the coverage proportion of one visit of 
antenatal care, four visits of antenatal care, skilled birth attendance, and in-facility delivery. 
Several new covariates were introduced in this analysis in recognition of their potential 
relation to maternal mortality, all of which were specified as level 3. Obesity prevalence was 
added to help to reflect the added complexity of care and heightened risk of maternal 
complications in those who are obese.29,30 Mortality death rate from fatal discontinuities, a 
covariate that aggregates the effects of war, famine, and natural disaster, was introduced to 
help to inform maternal mortality estimates in geographies where demographic shocks have 
led to interruption of vital statistics and where health systems are also hypothesised to have 
deteriorated.31,32 Hospital beds per 1000 population was added based on the hypothesis 
that it might be a proxy for the availability of basic EmOC.33 SDI, based on principal 
component analysis of fertility, maternal education (years per capita), and lag-distributed 
income (international $ per capita), was added as a covariate to all CODEm models in GBD 
2015. The root-mean SE of the top-performing ensemble model was 0·318 for the CODEm 
model of countries with extensive complete vital registration model and 0·553 for the global 
model. In-sample and out-of-sample data coverage was 99·6% and 99·3%, respectively, for 
the CODEm model of countries with extensive complete vital registration, and 98·3% and 
97·7%, respectively, for the global model. The relative contributions of each of the 
covariates and submodel performance for all component models in the top-performing 
CODEm ensemble are shown in the appendix (pp 662–75).
Modelling underlying cause and timing of maternal mortality
Our approach to quantify underlying cause and timing of maternal deaths was largely 
unchanged from GBD 2013, although in some cases we changed cause names to better 
reflect the ICD-9 and ICD-10 codes contained therein. ICD-9 and ICD-10 codes 
corresponding to each category are in the appendix (p 653). We examined six groups of 
direct obstetric causes, including maternal hypertensive disorders; maternal haemorrhage; 
maternal abortion, miscarriage, and ectopic pregnancy; maternal obstructed labour and 
uterine rupture; maternal sepsis and other maternal infections; and other maternal disorders. 
Two categories of indirect obstetric causes included maternal deaths aggravated by HIV/
AIDS and indirect maternal disorders. Late maternal deaths occurring between 42 days and 
1 year after the end of pregnancy were estimated as a separate cause (ICD-10 code, O96). 
Two differences can be noted between the GBD and ICD-maternal mortality modification 
classification systems, neither of which are new in this study, but nonetheless warrant 
mention in that they each reflect important clinical aspects of pregnancy complications. 
First, the GBD has grouped uterine rupture with obstructed labour rather than maternal 
haemorrhage, in recognition that most uterine rupture cases are secondary to inadequately 
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addressed or prolonged obstruction of labour. Second is the combining of abortion, ectopic 
pregnancy, and miscarriage into one cause. Although there are important differences 
between them, we treated them similarly with the rationale that safe interventions can be 
similar during early pregnancy (eg, medication, potentially dilation, and evacuation), as can 
management of life-threating complications such as infection and bleeding, which require 
prompt evaluation, diagnosis, and often emergency surgical intervention. We also examined 
four distinct time windows of maternal death. In addition to late maternal deaths, we 
estimated deaths occurring during the antepartum period (before onset of labour), 
intrapartum and immediate post partum (onset of labour up to <24 h after delivery), and 
early and delayed post partum (24 h to 42 days after delivery). We analysed late maternal 
death as both a timing category and as a distinct cause because the underlying causes of late 
maternal deaths are not specified in most data sources.
Systematic literature reviews identified studies that examined underlying causes and timing 
of maternal deaths (figure 1, step 7). We extracted additional information from specialised 
studies such as confidential enquiries and maternal mortality review boards that were 
obtained from targeted web searches or from correspondence with GBD collaborators. We 
supplemented aetiology models with cause-specific data from the causes-of-death database. 
Of note, our criteria for including data from the causes-of-death database was modified from 
GBD 2013 to include all data from any source where specific subcauses were coded rather 
than limiting to only those sources where the complete complement of subcauses were 
included. This change had the effect of substantially increasing the size of our analytical 
dataset with respect to time and geography. Late maternal death data from the causes-of-
death database were limited to those location years where at least 0·5% of all maternal 
deaths in raw vital registration data files were coded to late maternal deaths as this was the 
lowest proportion reported in any surveillance studies.34 Only 39 countries met these 
criteria with variable times in which they began coding late maternal deaths. Timing models 
were additionally supplemented with temporal information about pregnancy-related deaths 
from Demographic and Health Surveys maternal mortality modules. These data only 
reported on antepartum, intrapartum, and post-partum death. To maximise the volume and 
geographical distribution of data to inform causal attribution, we again modelled the 
proportion of deaths due to each cause and timing category using DisMod-MR 2.1.
The exception was HIV-related maternal mortality, for which the proportion was estimated 
using the population attributable fraction approach described above (figure 1, step 9). All 
data for cause and timing models for which late maternal death was excluded were 
statistically crosswalked within DisMod-MR 2.1 to the reference definition where late 
maternal death is included. Analytical details of DisMod-MR have been previously 
described.10 Further description, including details about updates contained in DisMod-MR 
2.1 and statistical crosswalks, are also included in the appendix (pp 21–24). To correct for 
ascertainment bias inherent in the introduction of late maternal death partway through the 
MDG period, we corrected overall maternal mortality estimates for the systematic exclusion 
of late maternal death in those location years where it was not coded (figure 1, step 10). 
Selection criteria to identify those geographies and years to be corrected are described 
above. Geographies where coding of late maternal deaths was introduced partway through 
the time period were only corrected for the years before introduction. Age-specific, year-
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specific, and geography-specific proportions predicted by DisMod-MR 2.1 for underlying 
causes and timing were then applied to the overall maternal mortality model developed in 
CODEm (figure 1, step 11).
Ensuring consistency with all other causes of death
Another crucial strength of the GBD approach to maternal mortality is that all results are 
internally consistent with all other specific causes of death (figure 1, step 12). CoDCorrect is 
a process that uses a simple algorithm to scale all cause-specific deaths from all causes for 
each age group, sex, year, and location, and thereby ensures that the sum equals total all-
cause mortality. For maternal mortality, it further scaled the sum of all cause-specific and 
timing-specific estimates to equal the total for all maternal mortality. Further details on 
CoDCorrect and its implementation are described in the appendix (p 48).
Age groups and fertility
Previous analyses have truncated evaluation of maternal mortality at 15 years to 49 years. 
Doing so ignores the non-trivial number of pregnancies and deaths occurring in those 
younger than 15 years and older than 50 years.35 Deaths in these age groups are routinely 
coded in our data sources, so for the first time, we have expanded the age range of our 
maternal mortality analysis to include all 5-year age groups from 10 years to 54 years in 
GBD 2015. To facilitate calculation of MMR in these age groups, our demographic analysis 
included expansion of UN Population Division estimates of age-specific livebirths to include 
10–14 years and 50–54 years (figure 1, step 13). The appendix (pp 49–50, 684–701) 
provides more detail on fertility estimation in these age groups and a table of age-specific 
livebirths for all locations.
Uncertainty analysis
We report 95% UIs for all estimates. UIs include uncertainty introduced by variable sample 
sizes, data adjustments for all-cause mortality sources, and cause-specific model 
specifications and estimation. In CODEm, after a model weighting scheme has been chosen, 
each model contributes a number of draws proportional to its weight such that 1000 draws 
are created. The mean of the draws is used as the final estimate for the CODEm process and 
95% UI are created from the 0·025 and 0·975 quantiles of the draws. In DisMod-MR 2.1, 
uncertainty is calculated by sampling 1000 draws from the posterior distribution of each 
most-detailed geography, age group, and year. UIs for underlying causes and timing are 
propagated from the combination of CODEm and DisMod-MR 2.1 draws. We propagated 
uncertainty into all the final quantities of interest at all levels of geographic, temporal, and 
age-specific aggregations assuming no correlation between them.
Analysis of levels and trends
MMR, annualised rate of change, and reporting metrics—We report number of 
deaths and MMR; number of deaths per 100 000 livebirths) for ages 10–54 years inclusive. 
We calculated MMR for each 5-year age group separately using age-specific livebirths 
(figure 1, step 14). We calculated annualised rate of change (ARC) using the two-point 
continuously compounded rate-of-change formula36 in each geography separately for 1990–
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2000, 2000–15, 1990–2015, and all single years throughout the time period. ARC 
examination shows overall trends, highlights periods of acceleration (or deceleration) in 
improvement, and allows identification of those countries that probably achieved MDG 5.
Drivers of change in the MDG era, coverage target setting for SDGs—For GBD 
2015, we completed two additional analyses to systematically describe drivers of levels and 
trends in maternal mortality. First, we examined the relation between MMR and SDI, a 
summary indicator derived from measures of income per capita, educational attainment, and 
fertility using the Human Development Index method.37 The SDI has an interpretable scale: 
zero represents the lowest income per capita, lowest educational attainment, and highest 
total fertility rate noted across all GBD geographies from 1980 to 2015 and one represents 
the highest income per capita, highest educational attainment, and lowest total fertility rate. 
We then used spline regression to calculate the average relation between MMR and SDI, 
thereby facilitating further evaluation of geographical and temporal MMR trends. Further 
details of SDI development and spline regressions are in the appendix (p 48). We then used 
the average relation between SDI and MMR to calculate observed minus expected (O–E) 
MMR ratio and O–E ARC (from 2000 to 2015), respectively, to show average patterns that 
can help to benchmark a country against other countries and provides insights into whether 
or not public action or other factors have been leading to narrowing—or growing—
inequalities since the MDG declaration. Second, to capture how improvements in women’s 
access to the specific modes of reproductive health care might change the average relation 
observed between SDI and MMR, we also examined the relation between MMR and 
coverage of one visit of antenatal care, four antenatal care visits (a proxy for more 
comprehensive care), in-facility delivery, and skilled birth attendance by calculating the 
average coverage of each over different MMR ranges.
Role of the funding source
The funder of the study had no role in the study design, data collection, data analysis, data 
interpretation, or writing of the report. The authors had access to the data in the study and 
had final responsibility for the decision to submit for publication.
Results
Global and country-specific maternal mortality
Global maternal deaths decreased slightly from 390 185 (95% UI 365 193–416 235) in 1990 
to 374 321 (351 336–400 419) in 2000 before dropping to 275 288 (243 757–315 490) in 
2015 (figure 3). The overall decrease from 1990 to 2015 in global maternal deaths was 
roughly 29% and the decrease in MMR was 30%. Table 1 shows results for all specific 
geographies in the GBD hierarchy. MMR followed a similar trend to overall maternal 
deaths; MMR was 282 (95% UI 264–300) in 1990, 288 (270–308) in 2000, and decreased to 
196 (173–224) in 2015. Global ARC was –1·5% (95% UI –2·0 to –0·9) across the entire 
MDG period from 1990 to 2015. Global ARC was initially relatively flat at 0·2% (–0·5 to 
0·9) from 1990 to 2000, but accelerated greatly after the Millennium Declaration to be –
2·6% (–3·4 to –1·7) from 2000 to 2015. Looking at single-year ARC, we see the global 
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acceleration began in the year 2001 and has continued accelerating until 2007–08, after 
which the rate of improvement has slowed.
Geographical differences in maternal mortality are readily apparent. In 1990, 60 countries 
had an MMR greater than 200, 40 countries had an MMR of greater than 400, and 15 greater 
than 600 (appendix pp 58–62). Only one country—Burundi—had an MMR greater than 
1000. MMR was less than 70 in 93 countries at that time. A subset of 50 countries had an 
MMR of less than 30, and 28 countries were less than 15. By the year 2015, as shown in 
figure 4, 122 countries had an MMR of less than 70, and 49 countries had an MMR of less 
than 15, including Saudi Arabia, all countries in central Europe, and all high-income 
locations with the exception of the USA, Argentina, Brunei, Chile, and Uruguay. Several 
other countries in North Africa and Middle East along with the USA, Armenia, Azerbaijan, 
Bulgaria, Chile, China, Costa Rica, Kazakhstan, Puerto Rico, Romania, Russia, Tajikistan, 
Thailand, Turkmenistan, Ukraine, Uruguay, Uzbekistan, and Vietnam had an MMR between 
15 and 30. Unfortunately, there were still 24 countries with an MMR of greater than 400, 
eight countries with greater than 600, and still one—Central African Republic—greater than 
1000. Of those greater than 600, Sierra Leone, Afghanistan, and Central African Republic 
actually worsened, with ARC from 1990 to 2015 of 2·7% (–1·3 to 6·3), 0·34% (–2·1 to 2·7), 
and 0·08% (–5·5 to 4·9), respectively. Of those countries with an MMR higher than 400 in 
1990, Burundi and Equatorial Guinea improved substantially by 2015 with total 
improvements of –4·3% (–8·7 to 0·3) and –4·2% (–9·6 to 3·9), respectively.
MDG 5 achievement
To achieve the primary objective of MDG 5, the ARC must have met or exceeded an average 
of –5·5% during the entire time period from 1990 to 2015. Based on this metric, a total of 
ten countries probably achieved MDG 5, including Iceland, Jordan, Maldives, Belarus, 
Morocco, Romania, China, Turkey, Poland, and Estonia. Several other countries achieved 
this rate of improvement at some point during the MDG period. From 2000 to 2015, 24 
countries exceed ARC of –5·5%. Many countries, despite not achieving the ambitious MDG 
5 target of a 75% reduction, actually have been experiencing steady declines in maternal 
mortality for quite some time. 148 of 195 countries and territories saw their peak MMR 
occur before the year 2000, with an additional 21 occurring by the year 2005. Maternal 
mortality increased in 26 countries between 1990 and 2015.
Relation between MMR, SDI, and reproductive health services
As shown in table 2, maternal mortality in the lowest SDI quintile improved the least, with 
ARC of only –0·97% (–1·8 to –0·001) from 1990 to 2015, and the low-middle SDI quintile 
was the next slowest with an ARC of –2·1% (–2·8 to –1·1). The proportion of all maternal 
deaths occurring in the bottom two SDI quintiles increased from roughly 68% in 1990 to 
more than 80% in 2015. The middle SDI quintile improved the fastest with ARC of –3·2% 
(–3·8 to –2·6) over the entire time period. Figure 5 shows global and regional-level MMR 
and SDI from 1990 to 2015. The black convex line represents the average relation between 
MMR and SDI over the time period and is the basis of expected MMR. Each coloured 
symbol represents a successive year from 1990 to 2015 for the global level and GBD 
regions. Globally, MMR in 2015 was more than double what would have been predicted 
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solely by average SDI. This was following a period from 1990 to 2000 where global MMR 
improved more slowly than would have been expected based on SDI improvement and a 
period of faster-than-expected MMR improvement from 2000 to 2015. Based on the 
expected relation between MMR and SDI, reaching the SDG 3.1 achievement threshold of 
MMR 70 would require an SDI of 0·65, corresponding to an average income of roughly 
international $9442 per capita, 8·2 years of education, and total fertility rate of 2·5. Not all 
countries might be able to achieve that level of income, however, but education and fertility 
reduction efforts could still be compatible with reaching this SDI level. If all women were to 
complete a full 12 years of education and total fertility rate of 2·7, an SDI of 0·65 would on 
average be associated with income of $3214 per capita. If total fertility rate were to decrease 
further to the population replacement rate of to 2·0 and education were 12 years, this SDI 
level would only require an annual income of $2648 per capita.
MMR and SDI both improved between 1990 and 2015 in almost all regions, but MMR did 
not universally track with SDI over the entire time period in any single region. East Asia has 
had the lowest O–E MMR ratio since 2011, a period in which it has consistently been less 
than 0·4 of expected. Australasia has also had consistently lower MMR than would be 
predicted on the basis of SDI, with O–E MMR ratio ranging from 0·54 in 1990 to 0·71 in 
2015. In addition to east Asia and Australasia, several other regions have consistently had 
lower MMR than would have been expected by SDI, including central Asia, central Europe, 
eastern sub-Saharan Africa, Western Europe, and high-income Asia Pacific. Southern Latin 
America and north Africa and the Middle East both had lower than expected MMR in 1990 
when both had O–E MMR ratios of less than 0·7, but improvement has not kept pace with 
SDI gains in either region: by 2015, O–E MMR ratios were 2·23 and 1·41, respectively. 
Central sub-Saharan Africa has been an exception in several ways. In addition to having the 
highest MMR of any region in 2015, MMR worsened from 1990 to 2015. Despite maternal 
mortality being high in central sub-Saharan Africa, it was still lower than would have been 
expected until 2014 because SDI is still so low in that region and has improved only slowly.
O–E MMR ratio has consistently been 1·25 or more in a larger number of regions, including 
the Caribbean, eastern Europe, high-income North America, Oceania, south Asia, southeast 
Asia, and southern sub-Saharan Africa. Andean Latin America had periods of rapid 
improvement in MMR during the early 2000s that exceeded that expected based on SDI. 
Unfortunately, MMR reductions there have slowed substantially since then, to the point 
where O–E MMR ratio was 1·41 in 2015. Improvements in eastern Europe have been faster 
than SDI after the year 2000, but MMR improvement in the remaining regions has continued 
to be slower than expected on the basis of SDI. Southern sub-Saharan Africa and the 
Caribbean had the highest O–E MMR ratios of any regions at 3·57 and 3·71, respectively, in 
2015, but both have had recent periods of MMR improvement that were much more rapid 
than expected on the basis of SDI. These trend reversals began in 2006 and 2007, 
respectively. South Asia and southeast Asia are unique in that although both have made 
major gains in terms of SDI and MMR, the difference between observed and expected MMR 
based on SDI remained the same.
Even within regions, the degree to which MMR diverged on the basis of SDI varied. For 
each country, we calculated observed ARC minus expected ARC (O–E ARC) on the basis of 
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SDI change from 2000 to 2015 (figure 6). In 60 countries, the O–E ARC was faster than 
would have been expected based on SDI alone, and 25 of these had ARC at least 1·5% faster 
than expected. Within south Asia, Bangladesh has improved faster than expected, whereas 
Nepal, Bhutan, and India all had slower MMR reductions. Of the countries in southeast 
Asia, Cambodia and Laos have improved much faster than expected, whereas Thailand, 
Philippines, and Malaysia have not. In sub-Saharan Africa, Namibia, Malawi, and Burundi 
were all more than 1·5% faster than expected, but ARC in most of the countries of eastern 
and western sub-Saharan Africa exceeded SDI-based expectations. By contrast, only Gabon 
in central sub-Saharan Africa reduced MMR as rapidly as expected, with the Democratic 
Republic of the Congo and Equatorial Guinea both more than 3% slower. 93 countries had 
an O–E ARC of 1·5% or more, and there were 17 countries where O–E ARC was greater 
than 5%.
To begin exploring the hypothesis that MMR improvements are related to coverage of 
specific modes of reproductive health care, we examined the relation between MMR and 
coverage of one visit of antenatal care, four antenatal care visits, in-facility delivery, and 
skilled birth attendance over the period from 1990 to 2015 (table 2). We found that, on 
average, countries with an MMR of less than 15 had 98% coverage of one antenatal care 
visit, 95% of four antenatal care visits, 97% of in-facility delivery, and 99% of skilled birth 
attendance. Those with an MMR of 70—the SDG 3.1 target for all countries—have roughly 
91% coverage of one antenatal care visit, 78% of four antenatal care visits, 81% of in-
facility delivery, and 87% of skilled birth attendance. This is by contrast with those countries 
with an MMR around 200 where there is an average of 84% coverage of one antenatal care 
visit, 61% of four antenatal care visits, 63% of in-facility delivery, and 70% of skilled birth 
attendance, and those locations with an MMR higher than 500 where coverage of all 
services was low, including just 76% coverage of one antenatal care visit, 45% of four 
antenatal care visits, 41% of in-facility delivery, and 48% of skilled birth attendance. 
Comparable datasets were not available to examine the relation between MMR and coverage 
of either EmOC, distance to obstetric care, post natal care coverage, or family planning 
services such as modern contraception and access to safe abortion services.
Age pattern of maternal mortality and fertility
The risk of maternal mortality increases greatly with age but decreased greatly in almost all 
age groups from 1990 to 2015 (appendix pp 63–295). Globally in 2015, MMR in 10–14 year 
olds girls was 278 (95% UI 229–339). MMR then decreased and was lowest in women from 
15–29 years old before increasing substantially to 1832 (95% UI 1284–2746) in 50–54 year 
olds (not shown on graph). Although the largest number of births still occur among women 
between the ages of 20 years and 29 years (55% of total), adolescent fertility has decreased 
in and a net shift in births to older women has been noted (appendix pp 684–701). In 1990, 
23·3 million (17% of total) livebirths occurred in those women aged younger than 20 years, 
and 0·58 million (0·42% of the total) were to girls aged 10–14 years. In 2015, 19·4 million 
(14% of total) births were in those aged 10–19 years, but there were still 0·48 million 
(0·34% of total) to girls younger than 15 years. By contrast, the absolute number of annual 
births to women aged 35 years and older increased from 16·1 million (12% of total) in 1990 
to 18 million (13% of total) in 2015. ARC in MMR among 10–19 year olds from 2000 to 
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2015 was –2·3 (95% UI –3·3 to –1·2), which was slower than the global ARC in MMR for 
all ages combined.
Cause pattern of maternal mortality
Although the risk of death from all causes increases with age, most deaths still occur in 
younger women and the absolute numbers of deaths from all causes except HIV are higher 
in younger age groups (see appendix pp 296–98 for number of deaths in 1990, 2000, and 
2015). Direct obstetric causes accounted for about 86% of all maternal deaths globally in 
2015, led by maternal haemorrhage, maternal hypertensive disorders, and other maternal 
disorders. This number is down only slightly from 1990 when direct complications 
accounted for 87% of all maternal deaths. Other maternal disorders decreased with the most 
of all causes between 1990 and 2015, from 74 299 (95% UI 61 159–89 653) deaths in 1990, 
down to 32 734 (26 256–40 507) deaths in 2015. Maternal abortion, miscarriage, and ectopic 
pregnancy, and maternal sepsis and other maternal infections were the causes with the next 
largest declines between 1990 and 2015. Indirect maternal disorders increased in importance 
from 1990 when they caused 42 246 (95% UI 32 355–54 032) deaths (about 11% of total) to 
2015 when they caused 33 108 (25 463–43 344) (about 12% of total). HIV-related maternal 
deaths were responsible for a portion of the increase in indirect maternal deaths, rising from 
754 (95% UI 433–1095) globally in 1990, peaking in the year 2000, and coming down to 
2322 (1394–3337) in 2015; this was 0·84% of overall maternal mortality in 2015. 2181 
(95% UI 1306–3174) of HIV-related maternal deaths were in sub-Saharan Africa in 2015, 
roughly 1·6% of the total there. Overall, the contribution of HIV to overall maternal death 
was quite small, but a large number of women with HIV/AIDS are dying incidentally while 
pregnant or after delivering. If we include incidental HIV deaths during pregnancy from our 
population attributable fraction analysis, 20 180 (95% UI 12 120–29 005) HIV-positive 
women died while pregnant or post partum in 2015 (appendix pp 720–37 shows cause-
specific maternal deaths for all GBD locations).
Changing cause pattern by age
The age pattern for underlying maternal mortality causes in 2015 (figure 7) shows that in the 
youngest age groups, maternal haemorrhage and maternal hypertensive disorders are the 
dominant causes, together accounting for more than 50% of all maternal deaths. Although 
the comparative risk associated with maternal hypertensive disorders decreases with age, 
haemorrhage actually peaked in importance in the 35–39 year olds. The contribution of most 
other causes of maternal death also increased with age, especially other direct maternal 
disorders and the combined category of abortion, ectopic pregnancy, and miscarriage. Late 
maternal deaths decreased steadily in importance from 1990, when 8460 (95% UI 5792–11 
935) late maternal deaths occurred, to 2015, when 6711 (4335–9996) occurred, and still was 
the time period with the smallest absolute number of deaths (see appendix pp 738–69 for 
timing deaths). The antepartum and post-partum periods were the periods with the largest 
numbers of deaths in 2015 at 101 774 (95% UI 88 185–117 570) and 85 686 (72 956–101 
862), respectively. The age pattern showed that the proportion of post-partum deaths peaked 
in the youngest age groups, whereas intrapartum and antepartum deaths were more 
important in those older than 35 years (appendix pp 299–302). If we look at the change in 
underlying causal patterns as predicted by SDI (figure 8), we see that in the lowest SDI 
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geographies, maternal mortality is dominated by maternal haemorrhage. In high-SDI 
geographies, by contrast, the causal pattern changes substantially to one where other direct 
maternal disorders, indirect maternal disorders and abortion, ectopic pregnancy, and 
miscarriage are the most important causes of maternal death. In middle-SDI geographies, the 
epidemiological profile is even more complicated, with a particularly high proportion of 
maternal deaths being due to maternal hypertensive disorders.
Discussion
In summary, the overall change from 1990 to 2015 in global maternal deaths was roughly –
29% and in MMR was –30%, both of which were well short of the MDG 5 goal of –75%. 
Global maternal deaths were largely unchanged from 1990 to 2000, decreasing only slightly 
from 390 185 (95% UI 365 193–416 235) in 1990 to 374 321 (351 336–400 419) in 2000. 
Progress in MMR during the 1990s was also virtually undetectable when global ARC was 
only 0·21% (–0·46 to 0·87). This was 4·1% slower than would have been expected on the 
basis of SDI alone. After the Millennium Declaration, maternal mortality improvements 
accelerated. In 2015, there were 275 288 (95% UI 243 757–315 490) maternal deaths, and 
average global ARC in MMR from 2000 to 2015 was –2·6% (–3·4 to –1·7), although even 
with acceleration progress was 1·8% slower than would have been expected on the basis of 
SDI improvements alone.
Only ten countries achieved MDG 5 based on this analysis: Iceland, Jordan, Maldives, 
Belarus, Morocco, Romania, China, Turkey, Poland, and Estonia. Although overall progress 
has been slow during the MDG era, recent accelerations mean there are an additional 24 
countries where ARC has met or exceeded the MDG 5 achievement rate between 2000 and 
2015. There was significant variability in MMR throughout the world in 2015, ranging from 
a low of 0·8 (95% UI 0·6–0·9) in Iceland to a high of 1074 (215–2857) in Central African 
Republic. 122 of 195 countries had MMR in 2015 that is already less than the SDG 3·1 goal 
of 70.
Impediments to MMR reduction are multifaceted and variable; many are also well-
conceptualised through the lens of our SDI analysis. First, slow improvement in the two 
lowest SDI quintiles is one of the primary reasons that maternal mortality reduction has been 
slower than expected at the global level. In 1990, these two quintiles collectively accounted 
for 68% of maternal mortality, but by 2015, increased to more than 80% of the global total. 
Part of the reason is that high adolescent fertility rates in these locations, coupled with 
comparatively slow improvement in adolescent MMR, led to concentration of maternal 
mortality burden in young women and girls and higher total fertility in these populations. 
Second, some middle SDI locations might be experiencing a period of inertia where 
progress is stalling because health systems have not evolved to meet the challenge of 
identifying and managing high-risk pregnancies and efficiently responding to rapid clinical 
deterioration. Middle SDI geographies have historically had a higher proportion of cases due 
to conditions such as hypertensive disorders of pregnancy and other direct maternal 
disorders (eg, cardiomyopathy and embolism). Maternal haemorrhage also evolves with 
increasing SDI because, as increased in-facility delivery and skilled birth attendance lead to 
near universal active management of the third stage of labour, an increasing proportion of 
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remaining haemorrhage cases—especially those that result in death—will be due to 
intractable uterine atony or placental disorders, both of which require high levels of 
performance and responsiveness from horizontally integrated health systems.38 This treatise 
is supported by the observation that many of the countries or regions that improved more 
rapidly than would have been expected after 2000 were also the biggest recipients of 
Development Assistance for Health,39 funds that are often directed toward strengthening 
health systems, while many of those that have improved more slowly than expected have 
suffered from epidemics, natural disasters, and armed conflicts that impair the function of 
health systems and the willingness or ability of women to seek care. Third, within any given 
region, heterogeneous or slower-than-expected MMR improvements might be related to 
uneven ramp-up of coverage for specific method of reproductive health care— antenatal 
care, in-facility delivery, skilled birth attendance, family planning services, EmOC, and post 
natal care—that are all known to decrease the risk of bad pregnancy outcomes.40,41 Indeed, 
increasing use of reproductive health services was one of the driving factors behind 
establishment of the Janani Suraksha Yojana conditional cash transfer programme in India. 
Janani Suraksha Yojana has been successful at increasing reproductive health-care services, 
but even despite its popularity this programme has not been as effective at reaching poor 
rural women, the sociodemographic group that is already at highest risk of adverse 
pregnancy outcomes.42 In addition to the Janani Suraksha Yojana programme in India, other 
countries such as Nepal, Mexico, El Salvador, Honduras, Guatemala, Uruguay, and Brazil 
have also had success in encouraging use of reproductive care services,43,44 so this might 
be a viable option for countries seeking to increase women’s use of reproductive health-care 
services. Fourth, the highest SDI geographies are likely also experiencing a confluence of 
factors leading to higher-risk pregnancies and subsequently higher than expected MMR—
namely, delay of fertility to older ages and a corresponding increase in the proportion of 
pregnant women with non-communicable diseases (NCDs). Other direct maternal disorders 
are the dominant cause of maternal death in high SDI locations, driven by cardiomyopathy 
and obstetric embolism, both of which are of higher risk in older women and those with 
preexisting conditions such as hypertension, obesity, and diabetes.45,46 If the trend of 
increasing NCDs continues and, barring any breakthrough in preventing such complications, 
we could reasonably expect to see MMR increases begin to emerge in other regions besides 
those in the highest SDI.
Because of the importance of reproductive care coverage in overall reproductive health, and 
to help to guide specific coverage targets for achieving SDG 3.1 and 3.7, comparable metrics 
and monitoring on coverage of all of these reproductive health services should be integrated 
into regular progress reports at the global, regional, national, and subnational levels, 
including the development of comprehensive strategies to reach those targets. Our analysis 
found that an MMR of 70 is expected with an SDI level of 0·65, which corresponds to an 
average income of international $2648 per capita, a total fertility rate of 2·0, and completing 
12 years of education, so even lower income countries might have a path to SDG 3.1 
attainment. An MMR of 70 is also associated with about 91% coverage of one antenatal care 
visit, 78% of four antenatal care visits, 81% of in-facility delivery, and 87% of skilled birth 
attendance. Higher MMR locations have historically had much lower coverage of these 
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services, particularly in-facility delivery and skilled birth attendance, and increasing access 
to them will require sustained focus.
Quality of care must also be a focus as coverage of family planning services, antenatal care, 
in-facility delivery, skilled birth attendance, EmOC, and postnatal care increase, because the 
existence of these programmes by themselves is not sufficient to ensure that women are 
receiving the care they need during pregnancy and the post-partum period.47 Care should be 
integrated and not be focused on single vertical interventions.48 Family planning services 
should be longitudinal and include provision of comprehensive sex education, multiple 
methods of modern contraception, and access to safe abortion.49 High-quality antenatal care 
should reflect appropriate use of services, good communication between patient and 
provider, and reliable screening and treatment for infectious diseases (eg, sexually 
transmitted infections), chronic conditions (eg, blood disorders, obesity, substance abuse, 
renal dysfunction, rheumatic, or other heart disease) and pregnancy abnormalities (eg, 
anaemia, nutritional deficiencies, blood pressure, glucose, urine protein, fetal growth 
anomalies).50,51 In-facility delivery and skilled birth attendance services must be 
adequately staffed to meet demand and, because not all major complications of pregnancy 
are avoidable or easily predictable, women need to have ready access to well-functioning 
basic and comprehensive EmOC services. These services must be appropriately distributed 
to meet demand52 and be staffed by sufficient numbers of trained midwives, nurses, and 
anaesthesia and obstetrical providers to meet demand, including on nights and weekends. 
Health professionals in EmOC facilities also need to have appropriate equipment including 
medications, access to blood transfusion materials, and intensive care services to help to 
prevent complications from leading to death.53,54 Post natal care should focus on detection 
and treatment of those conditions known to be more common in the post-partum and late 
maternal period, including cardiomyopathy, pulmonary embolism, and renal complications.
55,56 In countries with generalised HIV epidemics, AIDS-related deaths have also been 
observed to commonly occur 42 days or more after pregnancy ends, and care efforts for 
HIV-positive mothers should focus on ensuring uninterrupted antiretroviral treatment.57,58
Late maternal death statistics need to be improved. Maternal mortality surveillance studies 
such as confidential enquiry have showed that late maternal death is non-trivial in even low-
resource settings34,59 and can account for up to 40% of maternal deaths in high-income 
settings.60 A contemporary linkage study in Mexico found that 18% of maternal deaths are 
missed when the definition is truncated at 42 days’ post partum.61 As immediate mortality 
continues to decrease as a result of improved antenatal, obstetric, and post-partum care, it is 
therefore increasingly likely that the proportion of late maternal deaths will continue to 
increase. Despite knowledge of its importance, only a few countries using ICD-10 reliably 
code late maternal deaths. This is especially egregious because many of the same countries 
who have completed multiple confidential enquiries also have not recorded a single late 
maternal death in their official statistics. Denmark, Ireland, Finland, and the UK all fall into 
this category. Australia, France, and South Africa likewise completed multiple confidential 
enquiries and have recorded a total of eight maternal deaths combined in the entirety of their 
official statistics. This is the exact inverse of the USA where no nationally comprehensive 
confidential enquiries have been completed (although some states have established maternal 
mortality review boards). The USA has high MMR for a high-SDI country—and is one of 
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the few where it is increasing—but following the lead of Mexico and much of Latin 
America, it is also one of the only countries that has proactively improved its civil 
registration system with addition of a pregnancy checkbox on the standard death certificate,
62 so it is possible that at least a portion of the increase is related to enhanced case 
ascertainment.62 The USA should learn from the experiences of other countries and 
consider implementing regular, comprehensive confidential enquiries into drivers of 
maternal mortality. Other countries and subnational locations should follow the lead of the 
countries of the Americas by adding pregnancy checkboxes to their official death certificates 
and also ensuring that cooperation between their national statistics office and confidential 
enquiries committees maximises data quality.
WHO also recently published a set of maternal mortality estimates for 1990 to 201563,64 as 
part of its collaboration with the UN Maternal Mortality Estimation Inter-Agency Group 
(MMEIG). MMEIG 2015 global results again show a steep decline in maternal mortality 
from 1995 to 2005, and some deceleration in the period 2005–15 when maternal and 
newborn health Development Assistance for Health increased rapidly. GBD 2015 shows 
relatively little progress in the 1990s, but acceleration in MMR declines particularly after 
2005. We have previously discussed some of the important differences between the 
analytical approaches used by GBD and MMEIG.65 These included differences in dataset 
content, data processing methods, all-cause mortality, model specification, quantification of 
uncertainty, the use of CoDCorrect to ensure consistency between all specific causes of 
death, and the fact that MMEIG 2013 combined three separate estimation methods for 
different categories of countries, whereas GBD uses one approach for all countries.
MMEIG has made some important modifications to their analysis since 2013—most notably 
implementation of a Bayesian approach that combines all countries into a single model to 
estimate maternal mortality cause fractions (the proportion of all deaths in the population 
that are due to maternal causes). These changes are especially apparent in estimates for a 
number of countries, including Bosnia and Herzegovina, Cyprus, Estonia, Finland, Georgia, 
Kiribati, Latvia, Malaysia, Mongolia, Romania, Russia, South Korea, and Sri Lanka. Figures 
comparing MMEIG 2015 and GBD 2015 data inputs and results for each country are 
contained in the appendix. The correlation in MMR between MMEIG 2015 and GBD 2015 
estimates is now 0·85 over the entire time period from 1990 to 2015; this compares to a 
correlation in MMR between GBD 2013 and MMEIG 2013 of 0·77. If we limit the 
comparison to 2005 to 2015, correlation in MMR increases to 0·89.
Figure 9 compares the country-specific trends from 1990 to 2015 between the two analyses. 
Whereas GBD 2015 identified only ten countries as likely having achieved MDG 5, MMEIG 
2015 found a total of 18 achieved the MDG 5 target. Because both groups use the same set 
of livebirths estimates from the UN Population Division, with the exception that GBD 2015 
estimated maternal mortality for the entire age range from 10–54 years, differences in 
fertility are unlikely to be a major driver of differences between the two results. Drivers of 
differences can thus be best summarised as being due to differences in maternal cause 
fraction estimates or differences in all-cause mortality numbers as shown in the appendix (pp 
499–518).
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Global MMR estimates in 1990 were much higher in the MMEIG 2015 analysis, driven 
largely by higher estimates of maternal cause fraction in sub-Saharan Africa, south Asia, 
central Asia, central Latin America, and north Africa and the Middle East. 2015 MMEIG 
all-cause mortality estimates for 1990 were also higher in many of these same regions as 
well as in tropical and Andean Latin America, all of which led to higher MMR estimates 
than those produced by GBD 2015. Of note, GBD 2015 maternal cause fraction estimates 
were higher in most high-income regions, central Europe, and Oceania. By contrast, our 
decomposition of the drivers of differences in 2015 estimates show that differences in 
maternal cause fraction and all-cause mortality estimates narrowed in south Asia, central 
Asia, and much of sub-Saharan Africa, which has on aggregate led to broad agreement in 
global MMR figures for 2015. GBD 2015 estimates of maternal cause fraction estimates 
remain notably higher in high-income North America, western Europe, and Oceania, 
although it is likely that much of this is driven by MMEIG 2015 exclusion of late maternal 
mortality.
The total number of sources used by MMEIG 2015 was 203 and by GBD 2015 was 599 
(appendix pp 677–83 shows all country-specific sources by type used in each analysis). For 
a number of populous countries—including China, Ethiopia, Indonesia, and India—
differences in maternal cause fraction estimates are largely driven by dataset content. 
MMEIG 2015 did not include data from Medical Certification of Cause of Death66 or the 
Survey of Causes of Death67 from India, several years of census and verbal autopsy data 
from Indonesia and Ethiopia, and maternal mortality surveillance data from China. MMEIG 
2015 similarly did not include vital registration data from Iran and the Dominican Republic 
or sibling history from Jordan, all of which led to very different estimates of levels and 
trends of maternal mortality in those countries. In total, 396 sources were excluded by 
MMEIG 2015. In many cases the MMEIG 2015 documentation does not describe reasons 
for not including these data. In future iterations of both the GBD and MMEIG estimation, 
the groups should both work more closely to ensure relevant data sources are included in 
both analyses.
Differences in processing methods of sibling history data are important, especially for 
countries in sub-Saharan Africa. The nine countries without maternal mortality data in the 
GBD 2015 analysis were Andorra, Angola, Equatorial Guinea, the Federated States of 
Micronesia, Marshall Islands, Samoa, Solomon Islands, Somalia, and Vanuatu. MMEIG 
2015 had no data for 23 GBD 2015 countries or territories, including Angola, Djibouti, 
Federated States of Micronesia, Guinea Bissau, North Korea, Palestine, Papua New Guinea, 
Samoa, Solomon Islands, Somalia, Tonga, and Vanuatu. They did not generate estimates for 
American Samoa, Andorra, nd Barbuda, Bermuda, Dominica, Greenland, Guam, Marshall 
Islands, Seychelles, Taiwan, and the Virgin Islands.
GBD 2015 used single-year sibling history survival data from each source, applied Gakidou-
King weights to adjust for survivor bias, corrected for incidental HIV deaths using country-
year-age-specific information about the population attributable fraction of HIV to maternal 
death, and used Bayesian noise-reduction algorithms to help to reduce stochastic variability 
in data. On aggregate, this approach maximises capture of underlying information about 
levels and trends of pregnancy-related mortality in health surveys. MMEIG 2015 combined 
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all data from each survey and assigned them to the midpoint year of the recall period. They 
then uniformly applied a correction factor to reduce every datum by 10% or 15%, depending 
on the geography. The resulting MMEIG dataset is fairly sparse in some locations, and 
estimates are driven by regression coefficients. Examples can be seen in Democratic 
Republic of the Congo, Ethiopia, Ghana, and Saudi Arabia (see appendix pp 303–498). We 
would encourage MMEIG to consider using single-year sibling history data in their future 
analyses, because this difference in data processing might be driving divergence in trends 
from the early part of the MDG period, especially in sub-Saharan Africa.
Another important dataset difference is in the method used for processing and adjustment of 
vital registration data. GBD uses a standardised approach for all causes of death, empirically 
analysing every location’s single-year vital registration quality to guide dynamic 
adjustments to raw data (appendix pp 519–652). In past studies, MMEIG applied a default 
correction factor of 1·5 to all vital registration data. That method was modified in two ways 
in 2015. First, correction factors for vital registration were adjusted to match the deaths in 
published surveillance studies for those countries that had completed them. Second, MMEIG 
2015 reclassified selected recent years of vital registration data as special studies. These 
reclassified years were not subjected to the 1·5 correction factor, but earlier years were. This 
reclassification resulted in estimates showing faster declines in the MMR than are supported 
by raw data. These eight countries where the MMEIG results are affected by the selective 
vital registration reclassification are Brazil, Costa Rica, Cuba, Ecuador, Guatemala, 
Kazakhstan, Mexico, and Uruguay. The criteria used for reclassification of vital registration 
as special studies are not clearly documented, and it is unclear if these criteria have been 
objectively applied to all country-years of vital registration.
MMEIG implemented a Bayesian approach to estimate maternal mortality for the first time 
in their 2015 estimates, which substantially improved their model fit in countries with long 
time series of data. However, the base MMEIG model still relied on a simple linear mixed-
effects model with only three covariates—gross domestic product, general fertility rate, and 
skilled birth attendance—and country random effects. By contrast, the GBD 2015 used four 
families of statistical models and used 15 different covariates to develop ensemble models 
that were chosen based on a robust out-of-sample validity testing. MMEIG models were 
developed for the aggregate age range of 15–49 years, while the GBD 2015 estimates were 
generated separately for nine different 5-year age bands ranging from 10–54 years. The 
latter approach has the noted advantage of being able to automatically adjust for 
compositional bias if the age structure of the sample population is different from the general 
population. This approach also facilitates insight into potentially divergent age trends in 
maternal mortality within individual populations, matching them with corresponding shifts 
in age-specific fertility. Such an approach is crucial to singling out—for example—the 
contribution of adolescent fertility to overall maternal mortality levels and trends in maternal 
mortality. We therefore believe age-specific maternal mortality estimates, covering the entire 
reproductive age range, should be standard practice.
While recognising the potential caveats of adult mortality rates estimated using sibling 
survival, we made important improvements in GBD 2015 in accounting for selection bias 
and recall bias. We incorporated the uncertainty around adult mortality rate into our all-
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cause mortality estimation process for countries affected by HIV/AIDS in the sub-Saharan 
Africa regions. We did this by using single-year data for adult mortality rate from sibling 
survival modules—instead of pooled data for 5-year periods—and the crude death rate due 
to HIV/AIDS into the space-time Gaussian process regression that generates adult mortality 
rate estimates. This approach helped to reconcile between all-cause mortality estimates 
based on demographic sources and the HIV-specific mortality estimates using EPP-
Spectrum, thus allowing us to better capture levels and trends of mortality in adult women, 
especially in western and central sub-Saharan Africa. By contrast, mortality estimates from 
World Population Prospects 2015 do not incorporate all available data, do not explicitly 
reconcile HIV-related and background mortality estimates, and for many countries are 
largely based on a tabular model life table system derived from that age pattern of mortality 
from countries in the 1950s and 1960s and a single entry parameter, the under-5 mortality 
rate. Such a system is likely to misrepresent the changing relation between mortality in child 
age groups and adult age groups68 and, as we see from World Population Prospects 2015, 
all-cause mortality estimates in the 1990s, might overestimate mortality in western and 
central sub-Saharan Africa.69
The GBD approach to quantification of uncertainty assumes that uncertainty is uncorrelated 
in all locations. MMEIG has in the past assumed uncertainty is 50% correlated and 50% 
uncorrelated. This approach has led to very large uncertainty intervals in many countries and 
at the global level in past reports. MMEIG 2015 has implemented a more rigorous statistical 
approach to estimate uncertainty but has chosen the non-standard step of reporting only 80% 
UIs, despite the general global health practice of reporting 95% UIs. The rationale provided 
for this decision was that 95% UIs cannot be reliably interpreted, although why 80% 
intervals are more interpretable is unclear. In the interests of transparency and comparability 
to other analyses such as the GBD, we hope that in future estimates MMEIG will provide 
95% UIs along with other narrower intervals.
This analysis, like many before it, has a number of limitations. First, despite continued 
increase in the size and breadth of our data sources, we still have no data for maternal 
mortality from several countries and territories. In several other locations, especially low-
SDI regions, we continue to rely on data reporting aggregate pregnancy-related deaths from 
surveys and censuses. Unlike verbal autopsy and vital registration sources, survey and 
census data sources do not differentiate between maternal and non-maternal (incidental) 
deaths during pregnancy. The degree to which underreporting due to survival and recall bias 
offsets overreporting due to inclusion of incidental deaths is unclear and is further reason to 
advocate for improved data collection efforts. Second, although we report results on the 
entire period from 1990 to 2015, because of large lag times in release of data we have not 
been able to include any data from 2015 and data from only 13 countries from 2014. Final 
2015 results are thus based on recent historical data and model results. Third, our CODEm 
models have limited ability to capture non-stochastic rapid increases and decreases that 
might occur as a result of epidemics such as Ebola virus and H1N1 influenza,70,71 armed 
conflicts,72 or other events. Fourth, this report has examined nine specific causal categories 
of maternal death, but this classification system is certainly not exhaustive. We have not 
evaluated the contributions of some important chronic conditions known to increase risk to 
pregnant women such as obesity, diabetes, heart disease, haemoglobinopathies, such as 
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sickle cell disease, chronic kidney disease, and chronic hypertension, or specific risk factors 
that might contribute to mortality. Our evaluation of ectopic pregnancy, abortion, and 
miscarriage together limits the ability to specifically quantify the burden of unsafe abortion. 
We likewise have not disaggregated the other direct obstetric complications category to 
quantify the relative importance of anaesthesia complications, cardiomyopathy, and 
pulmonary embolism, all of which are known to be important contributors to maternal 
mortality in many settings. Continuing to improve on the specificity of our analysis of the 
underlying cause of maternal death will be expected to improve the clinical use of GBD 
estimates. Fifth, while the GBD approach has the ability to provide excellent detail on 
geographic and temporal trends in maternal mortality, it has limited ability to explore 
subpopulations that are not geographically based, including indigenous populations or other 
high-risk groups who might have higher MMR due to cultural, religious, or other 
differences.
In conclusion, a shift from a relative target of percent reduction in MDGs to an absolute 
threshold target of an MMR of 70 in the SDGs has important ramifications. It will 
emphasise countries with high maternal mortality rates over those that have already achieved 
the goal. Such emphasis might be beneficial in that it should help to focus additional 
international attention and resources on those countries who have the farthest distance to go. 
On the other hand, pre-emptive so-called achievement of SDG 3·1 has the potential to sap 
political and financial investment in reproductive health in countries that still have major 
numbers of preventable maternal deaths, especially when continued progress is likely to 
depend largely on improvements in overall health systems performance.73–77 One approach 
to mitigate this risk would be to promote SDG 3.1 not only as a threshold goal for nations on 
aggregate, but also as a target for all subpopulations within each. This approach will require 
all stakeholders to make disaggregated data and information about women’s, children’s, and 
adolescents’ health publicly available.5 Furthermore, as the global community pursues SDG 
3.1, monitoring and reporting on all aspects of reproductive health care as outlined in SDG 
3.7 will be important.5 Achievement of this will require the international community to pay 
heed to the intricately related issues of immigration, armed conflicts, epidemics and 
pandemics, environment, economic instability, and gender equality, all of which can have 
substantial effects on the availability and quality of reproductive health services and 
women’s willingness to seek them.
Global progress in reducing maternal mortality has been accelerating in the past 15 years, 
but there is still major work left to do. More than 250 000 women died during or following 
pregnancy in 2015, most of which were preventable deaths. Every woman that died left 
children, widowers, family, and their communities behind. The quantitative effect of MDG 5 
is difficult to measure, but it is even harder to dispute the notion that it has united the 
international community in striving to decrease maternal mortality. With the ratification of 
SDG 3.1 and SDG 3.7, relevant stakeholders need to make informed decisions about how to 
prioritise actions needed to bring about continued progress, and they can only do that with 
better data. As we continue on the path toward 2030, necessary and urgent steps will include 
rapid improvement in cause of death data collection systems and data dissemination coupled 
with more effective and widespread action and policies to promote education of girls and 
women, provide them with comprehensive family planning services, and ensure that each 
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and every woman has access to the types of reproductive care they need to survive—and 
thrive.
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Research in context
Evidence before this study
Published in 2012, GBD 2010 presented results for 187 countries with a population 
greater than 50 000 in the year 2000. Collaborative teams completed subnational 
assessments for the UK, Mexico, and China for GBD 2013, expanding the number of 
geographies in the GBD analysis to 296. The value of subnational assessments to local 
decision makers has led to expansion of subnational analyses in GBD 2015 to also 
include Brazil, India, Japan, Kenya, Saudi Arabia, South Africa, Sweden, and the USA. 
Several previous analyses, including several completed as part of the Global Burden of 
Diseases, Injuries, and Risk Factors (GBD) Collaboration, have sought to provide the 
best possible information about levels and trends in maternal mortality. In dual 
recognition of both the importance and difficulty of accurately reporting on maternal 
mortality in many settings, each has incorporated increasingly large and geographically 
precise datasets and used more advanced statistical models. In their latest iteration, the 
WHO methods have also now adopted a single model for all countries and computed 
statistical uncertainty intervals. Important differences remain, however, that at times paint 
divergent pictures of levels and trends in maternal mortality globally and in many 
countries.
Added value of this study
The GBD 2015 assessment of maternal mortality provides new and more robust evidence 
on the levels and trends in maternal mortality in 195 countries and territories throughout 
the world as the MDG era has ended and the SDG era is beginning. It incorporates 
subnational data from an expanded group of countries that now includes Brazil, China, 
India, Japan, Kenya, Mexico, Saudi Arabia, South Africa, Sweden, the UK, and the USA. 
This study complies with the Guidelines for Accurate and Transparent Health Estimates 
Reporting (GATHER) recommendations. Further, this analysis extends the concept of 
sociodemographic status by introducing a new sociodemographic index for a more robust 
positioning of countries and territories on the development continuum.
Implications of all the available evidence
This study provides the most comprehensive assessment to date of patterns and levels of 
maternal mortality worldwide, expanding on previous analyses by including the full 
reproductive age range of 10–54 years, more comprehensively evaluating the interplay 
between maternal mortality, HIV/AIDS, and all-cause mortality, and reporting on how the 
coverage of reproductive health services relates to risk of maternal mortality. This study 
further investigates the main determinants of epidemiological patterns and trends across 
geographies and over time by comparing the observed maternal mortality, including eight 
underlying aetiologies of maternal mortality, with patterns expected on the basis of SDI. 
The GBD 2015 study entails a complete reanalysis of levels and trends from 1990 to 
2015; the time series published here therefore supersedes the results of the GBD 2013 
study. The expansion of geographic units, from 296 in GBD 2013 to 519 for GBD 2015, 
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is envisaged to continue so as to sustain comparability over time and across all 
geographies.
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Figure 1. Analytical flow chart for the estimation of maternal mortality for GBD 2015
Ovals represent data inputs, square boxes represent analytical steps, cylinders represent 
databases, and parallelograms represent intermediate and final results. Numbers are steps of 
the prcoess. The flowchart is colour-coded by major estimation component: data preparation 
and overall maternal mortality in blue; cause-specific and timing-specific estimation in 
green; analysis and data specific to the role of HIV/AIDS in maternal mortality in pink; 
steps related to demographic and computational processes that ensure internal consistency in 
orange, and final estimates in dark blue. GBD=Global Burden of Disease. ICD=Internatinal 
Classification of Diseases. COD=causes of death. Epi=epidemiology. DHS=Demographic 
and Health Survey. CODEm=causes-of-death ensemble modelling. RR=relative risk. 
MMR=maternal mortality ratio. WPP=World Population Prospects. EPP=Estimation and 
Projection Package. RR=relative risk. Preg+=pregnant. Preg–=non-pregnant.
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Figure 2. ICD-10 vital registration redistribution pattern from cause-specific and garbage codes 
to maternal-mortality specific GBD causes, global, all years combined
The list of causes on the left are raw ICD-10 cause codes according to death certification 
data sources and those on the right are the final target aetiologies for maternal mortality. The 
height of each bar is proportional to the number of deaths in each category. The colours are 
for ease of visualisation. Redistribution categories: A41=other sepsis; A419=sepsis, 
unspecified organism; D649=anaemia, unspecified; D65=disseminated intravascular 
coagulation; G809=cerebral palsy, unspecified; G931=anoxic brain damage, not elsewhere 
classified; I26=pulmonary embolism; I269=pulmonary embolism without acute cor 
pulmonale; I743=embolism and thrombosis of arteries of the lower extremities; 
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I749=embolism and thrombosis of unspecified artery; K650=generalised (acute) peritonitis; 
K659=peritonitis, unspecified; N179=acute kidney failure, unspecified; N19=unspecified 
kidney failure; O95=obstetric death of unspecified cause; R98=unattended death; R99=ill-
defined and unknown cause of mortality; ZZZ=causes violating age/sex limitations); 
reg_gc_left_hf_anaemia=anaemia due to left heart failure; other garbage=all other garbage 
codes. ICD-10=International Classification of Diseases 10. GBD=Global Burden of Disease.
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Figure 3. Global results with 95% uncertainty interval (UI) for maternal deaths, maternal 
mortality ratio (MMR; number of deaths per 100 000 livebirths), and annualised rate of change 
(ARC) in MMR by year, 1990–2015
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Figure 4. Maternal mortality ratio (MMR; number of deaths per 100 000 livebirths) for 
countries and territories, 2015
The map is colour-coded according to the national MMR in the year 2015. Lowest MMR is 
shown in purple and highest in dark red. Inset images help to show smaller countries. 
ATG=Antigua. VCT=Saint Vincent and the Grenadines. Isl=Islands. FSM=Federated States 
of Micronesia. LCA=Saint Lucia. TTO=Trinidad and Tobago. TLS=Timor-Leste.
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Figure 5. Co-evolution of maternal mortality ratio (MMR; number of livebirths per 100 000 
livebirths) with SDI globally and for GBD regions, 1990–2015
Coloured lines show global and region values for MMR. Each point in a line represents one 
year starting at 1990 and ending at 2015. In all regions, SDI has increased over time so 
progress in SDI is associated with points further to the right and later years for a given 
region. The black lines indicate expected trajectories for each geography expected on the 
basis of SDI alone. SDI=Socio-demographic Index.
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Figure 6. Difference between observed annualised rate of change (ARC) in maternal mortality 
ratio (MMR; number of deaths per 100 000 livebirths) and expected ARC on the basis of Socio-
demographic Index (SDI) alone from 2000 to 2015 for countries and territories
The map displays the difference between the observed average annual rate of change in 
MMR and the average annual rate of change that would have been expected based on the 
change in each country and territory’s SDI from 2000 to 2015. Values below zero indicate 
faster than expected progress while those above zero indicate MMR has improved more 
slowly than expected. ATG=Antigua. VCT=Saint Vincent and the Grenadines. Isl=Islands. 
FSM=Federated States of Micronesia. LCA=Saint Lucia. TTO=Trinidad and Tobago. 
TLS=Timor-Leste.
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Figure 7. Global proportion of total maternal deaths by underlying cause and age, 2015
The stacked area graph shows the proportion of total maternal deaths due to each cause 
globally in 2015 as a function of female age group.
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Figure 8. Expected relationship between cause-specific maternal mortality ratio (MMR; number 
of livebirths per 100 000 livebirths) and SDI (left) and proportion of maternal deaths due to each 
underlying cause and SDI (right)
These stacked curves represent the average relation between SDI and each cause of maternal 
mortality observed across all geographies over the time period 1990–2015. In each figure, 
the y axis goes from lowest SDI up to highest SDI. To the left of the midline are maternal 
mortality ratios (MMR; number of deaths per 100 000 livebirths), and the right-hand side 
shows the proportion of the total in order to highlight the different cause pattern in high SDI 
locations. SDI=Socio-demographic index.
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Figure 9. Comparison of annualised rate of change (ARC) in maternal mortality ratio (MMR; 
number of deaths per 100 000 livebirths) from GBD 2015 and MMEIG 2015 for all countries 
included in both analyses, 1990–2015
This scatterplot shows the net difference in average annualised rate of change (ARC) in 
maternal mortality ratio (MMR; number of deaths per 100 000 livebirths) estimates between 
GBD 2015 and MMEIG 2015 over the entire time period from 1990 to 2015. MMEIG 2015 
average ARC results are shown on the y-axis and GBD 2015 average ARC are shown on the 
x-axis. Points are colour-coded according to GBD super region. All countries under the 
horizontal dotted line were estimated by MMEIG to have achieved Millennium 
Development Goal (MDG) 5. Those to the left of the dotted line were estimated to have 
achieved MDG 5 by GBD 2015. UN Maternal Mortality Estimation Inter-agency Group. 
AFG=Afghanistan. BHS=The Bahamas. BLR=Belarus. BTN=Bhutan. BWA=Botswana. 
CAN=Canada. CHN=China. CMR=Cameroon. COD=Democratic Republic of the Congo. 
COG=Congo (Brazzaville). CPV=Cape Verde. DJI=Djibouti. EST=Estonia. FJI=Fiji. 
GUY=Guyana. IRN=Iran. ISL=Iceland. JAM=Jamaica. JOR=Jordan. KAZ=Kazakhstan. 
KHM=Cambodia. LAO=Laos. LBN=Lebanon. LBY=Libya. LSO=Lesotho. 
LUX=Luxembourg. MAR=Morocco. MDV=Maldives. MNG=Mongolia. POL=Poland. 
PRK=North Korea. ROU=Romania. RWA=Rwanda. SAU=Saudi Arabia. SLE=Sierra 
Leone. SRB=Serbia. SSD=South Sudan. SUR=Suriname. SWZ=Swaziland. TCD=Chad. 
TUR=Turkey. TLS=Timor-Leste. TON=Tonga. ZAF=South Africa. ZWE=Zimbabwe.
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Table 1
Global, regional, and national or territory number of maternal deaths, maternal mortality ratio (MMR; number 
of deaths per 100 000 livebirths), and annualised rates of change in percent, 1990–2015
Number of maternal deaths Maternal mortality ratio (per 100 000 livebirths) Annualised rate of change in maternal 
mortality ratio (%)
1990 2000 2015 1990 2000 2015 1990–2000 2000–15 1990–2015
Global 390 185
(365 193 to 
416 235)
374 321
(351 336 to 
400 419)
275 288
(243 757 to 
315 490)
 281·5
(263·6 to 300·3)
 287·6
(270·1 to 307·6)
 195·7
(173·4 to 224·2)
   0·2
(–0·5 to 0·9)
 –2·6
(–3·4 to –1·7)
 –1·5
(–2·0 to –0·9)
    High SDI      3811
(3615 to 4012)
     2505
(2400 to 2608)
     2108
(1990 to 2235)
   25·4
(24·1 to 26·8)
   19·1
(18·3 to 19·8)
   15·0
(14·2 to 15·9)
 –2·9
(–3·5 to –2·3)
 –1·6
(–2·1 to –1·1)
 –2·1
(–2·4 to –1·8)
    High-middle SDI   25 802
(23 828 to 28 
112)
  17 047
(15 867 to 18 
944)
  10 245
(9113 to 11 
423)
   86·9
(80·3 to 94·7)
   69·9
(65·1 to 77·7)
   41·9
(37·3 to 46·8)
 –2·2
(–2·9 to –1·3)
 –3·4
(–4·2 to –2·7)
 –2·9
(–3·4 to –2·5)
    Middle SDI   94 963
(87 723 to 103 
991)
  69 038
(63 737 to 75 
198)
  37 015
(32 496 to 42 
666)
 226·2
(209·0 to 247·6)
 201·2
(185·8 to 219·1)
 101·7
(89·4 to 117·2)
 –1·2
(–1·9 to –0·4)
 –4·6
(–5·5 to –3·5)
 –3·2
(–3·8 to –2·6)
    Low-middle SDI 196 860
(178 400 to 
216 483)
197 781
(180 988 to 
215 810)
135 086
(114 335 to 
166 218)
 496·7
(450·2 to 546·2)
 463·9
(424·5 to 505·7)
 298·2
(252·5 to 363·9)
 –0·7
(–1·8 to 0·4)
 –3·0
(–4·1 to –1·5)
 –2·1
(–2·8 to –1·1)
    Low SDI   68 497
(59 819 to 78 
539)
  87 679
(77 726 to 98 
833)
  90 639
(73 603 to 112 
175)
 560·9
(489·9 to 642·8)
 562·9
(499·0 to 634·5)
 443·2
(360·3 to 546·6)
   0·1
(–1·4 to 1·3)
 –1·7
(–3·1 to –0·1)
 –1·0
(–1·8 to 0·0)
    High income      2321
(2233 to 2419)
     1848
(1782 to 1920)
     1989
(1877 to 2109)
   18·9
(18·2 to 19·7)
   15·8
(15·2 to 16·4)
   16·9
(16·0 to 17·9)
 –1·8
(–2·3 to –1·4)
   0·5
(0·0 to 0·9)
 –0·5
(–0·7 to –0·2)
High-income
North America
      699
(668 to 734)
      727
(693 to 762)
      1091
(1016 to 1177)
   16·0
(15·3 to 16·8)
   16·7
(16·0 to 17·5)
   24·7
(23·0 to 26·7)
   0·5
(0·0 to 1·0)
   2·6
(2·0 to 3·2)
   1·8
(1·4 to 2·1)
    Canada         23
(20 to 27)
        26
(23 to 29)
        28
(24 to 34)
     6·0
(5·2 to 6·9)
     7·7
(6·8 to 8·8)
     7·3
(6·2 to 8·7)
   2·5
(0·8 to 4·3)
 –0·4
(–1·8 to 1·1)
     0·8
(–0·1 to 1·7)
    Greenland           1
(0 to 1)
          0
(0 to 1)
          0
(0 to 0)
   20·9
(15·5 to 29·0)
   21·2
(16·2 to 28·6)
   14·3
(10·4 to 20·9)
   0·1
(–3·0 to 3·3)
 –2·7
(–5·3 to –0·4)
 –1·5
(–3·3 to 0·1)
    USA       674
(644 to 711)
      700
(666 to 735)
     1063
(988 to 1 145)
   16·9
(16·2 to 17·8)
   17·5
(16·6 to 18·3)
   26·4
(24·6 to 28·4)
   0·3
(–0·2 to 0·8)
   2·7
(2·2 to 3·4)
   1·8
(1·4 to 2·1)
Australasia         26
(23 to 30)
        25
(22 to 28)
        25
(21 to 29)
     8·4
(7·4 to 9·6)
     8·1
(7·1 to 9·1)
     6·6
(5·6 to 7·7)
 –0·5
(–1·9 to 1·0)
 –1·4
(–2·6 to –0·1)
 –1·0
(–1·8 to –0·2)
    Australia         19
(16 to 22)
        19
(16 to 22)
        18
(15 to 21)
     7·5
(6·4 to 8·7)
     7·6
(6·6 to 8·7)
     5·5
(4·6 to 6·6)
   0·1
(–1·8 to 2·0)
 –2·1
(–3·5 to –0·7)
 –1·2
(–2·1 to –0·2)
    New Zealand           7
(6 to 8)
          6
(5 to 7)
          7
(6 to 9)
   12·6
(10·7 to 14·6)
   10·2
(8·7 to 12·0)
   12·0
(10·0 to 14·3)
 –2·1
(–4·2 to 0·0)
   1·1
(–0·5 to 2·6)
 –0·2
(–1·2 to 0·8)
High-income
Asia Pacific
      345
(319 to 371)
      192
(180 to 207)
      123
(112 to 135)
   17·2
(15·9 to 18·5)
   11·0
(10·3 to 11·8)
     8·0
(7·3 to 8·8)
 –4·5
(–5·4 to –3·6)
 –2·1
(–2·9 to –1·3)
 –3·0
(–3·5 to –2·6)
    Brunei           4
(3 to 5)
          3
(2 to 4)
          2
(2 to 3)
   48·2
(37·8 to 60·5)
   40·8
(33·7 to 48·6)
   33·5
(26·8 to 42·1)
 –1·6
(–4·4 to 0·9)
 –1·4
(–3·1 to 0·6)
 –1·5
(–2·9 to –0·1)
    Japan       164
(157 to 172)
      102
(97 to 108)
       66
(60 to 71)
   12·8
(12·3 to 13·5)
   8·8
(8·4 to 9·4)
     6·4
(5·8 to 6·9)
 –3·7
(–4·3 to –3·2)
 –2·1
(–2·9 to –1·6)
 –2·8
(–3·2 to –2·4)
    Singapore           5
(5 to 6)
          5
(5 to 6)
          2
(2 to 2)
   10·6
(9·3 to 12·1)
   11·5
(10·1 to 13·0)
     5·0
(4·3 to 5·8)
   0·9
(–0·9 to 2·4)  –5·5
*
(–6·8 to –4·4)
 –3·0
(–3·9 to –2·2)
    South Korea       171
(148 to 195)
        82
(72 to 93)
        53
(44 to 62)
   25·5
(22·1 to 29·1)
   15·1
(13·3 to 17·2)
   11·6
(9·6 to 13·6)
 –5·3
(–7·0 to –3·7)
 –1·7
(–3·3 to –0·3)
 –3·2
(–4·1 to –2·3)
Western Europe       617
(584 to 652)
      439
(417 to 461)
      315
(288 to 338)
   13·7
(13·0 to 14·5)
   10·2
(9·7 to 10·7)
     7·2
(6·6 to 7·7)
 –3·0
(–3·6 to –2·4)
 –2·4
(–3·0 to –1·8)
 –2·6
(–3·1 to –2·3)
    Andorra           0
(0 to 0)
          0
(0 to 0)
          0
(0 to 0)
     3·8
(1·9 to 5·5)
     2·5
(1·1 to 3·9)
     2·0
(1·1 to 3·0)
 –4·2
(–8·5 to –0·3)
 –1·6
(–4·4 to 3·3)
 –2·7
(–4·6 to 0·3)
    Austria         10
(9 to 12)
          6
(5 to 7)
          3
(3 to 4)
   11·6
(10·4 to 13·0)
     7·5
(6·7 to 8·3)
     4·2
(3·7 to 4·8)
 –4·4
(–5·8 to –3·0)
 –3·8
(–4·9 to –2·7)
 –4·0
(–4·8 to –3·3)
    Belgium         17
(15 to 19)
        12
(10 to 13)
        10
(8 to 11)
   14·1
(12·5 to 15·7)
   10·2
(9·1 to 11·4)
     7·4
(6·4 to 8·5)
 –3·2
(–4·7 to –1·9)
 –2·2
(–3·4 to –1·0)
 –2·6
(–3·4 to –1·9)
    Cyprus           2
(1 to 2)
          1
(1 to 2)
          0
(0 to 0)
   13·4
(10·1 to 17·4)
   12·0
(9·0 to 15·5)
     5·6
(4·1 to 7·2)
 –1·0
(–4·3 to 2·0)
 –5·2
(–7·8 to –2·3)
 –3·6
(–5·1 to –1·8)
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Number of maternal deaths Maternal mortality ratio (per 100 000 livebirths) Annualised rate of change in maternal 
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1990 2000 2015 1990 2000 2015 1990–2000 2000–15 1990–2015
    Denmark           6
(5 to 7)
          4
(3 to 4)
          3
(2 to 3)
     9·6
(8·3 to 11·0)
     5·8
(4·9 to 6·8)
     4·2
(3·5 to 5·1)
 –5·1
(–6·9 to –3·2)
 –2·0
(–3·6 to –0·6)
 –3·3
(–4·2 to –2·3)
    Finland           5
(4 to 6)
          4
(4 to 5)
          2
(2 to 3)
     7·9
(6·9 to 9·1)
     7·4
(6·5 to 8·6)
     3·8
(3·2 to 4·5)
 –0·6
(–2·3 to 1·3)
 –4·6
(–6·0 to –3·1)
 –3·0
(–3·8 to –2·1)
    France       126
(110 to 144)
        88
(76 to 99)
        61
(51 to 73)
   16·9
(14·7 to 19·3)
   11·7
(10·2 to 13·2)
     7·8
(6·5 to 9·3)
 –3·7
(–5·5 to –2·1)
 –2·7
(–4·3 to –1·2)
 –3·1
(–4·0 to –2·2)
    Germany       167
(151 to 187)
        85
(76 to 94)
        62
(54 to 70)
   20·2
(18·2 to 22·6)
   11·3
(10·2 to 12·6)
     9·0
(7·9 to 10·3)  –5·8
*
(–7·1 to –4·5)
 –1·5
(–2·6 to –0·4)
 –3·2
(–3·9 to –2·6)
    Greece         10
(9 to 12)
          9
(7 to 10)
          9
(8 to 11)
     9·7
(8·5 to 11·0)
     8·2
(7·2 to 9·3)
   10·0
(8·4 to 11·5)
 –1·6
(–3·2 to 0·0)
   1·3
(0·1 to 2·5)
   0·1
(–0·7 to 0·9)
    Iceland           0
(0 to 0)
          0
(0 to 0)
          0
(0 to 0)
     2·9
(2·5 to 3·4)
     1·2
(1·1 to 1·4)
     0·7
(0·6 to 0·8)  –8·6
*
(–10·5 to –6·9)
 –3·5
(–4·8 to –2·1)  –5·5
*
(–6·3 to –4·6)
    Ireland           4
(3 to 4)
          3
(2 to 3)
          3
(2 to 4)
     7·0
(5·7 to 8·4)
     5·1
(4·3 to 6·1)
     4·7
(3·6 to 5·9)
 –3·2
(–5·6 to –0·7)
 –0·6
(–2·7 to 1·5)
 –1·6
(–2·9 to –0·3)
    Israel         11
(10 to 13)
        10
(9 to 11)
        10
(8 to 11)
   11·1
(9·7 to 12·6)
     7·8
(6·8 to 8·7)
     5·8
(4·9 to 6·8)
 –3·6
(–5·2 to –1·9)
 –1·9
(–3·3 to –0·7)
 –2·6
(–3·4 to –1·7)
    Italy         56
(50 to 63)
        37
(32 to 42)
        21
(18 to 24)
   10·1
(9·0 to 11·4)
     6·9
(6·0 to 7·8)
     4·2
(3·6 to 4·9)
 –3·8
(–5·4 to –2·3)
 –3·3
(–4·6 to –2·0)
 –3·5
(–4·3 to –2·7)
    Luxembourg           0
(0 to 1)
          0
(0 to 0)
          1
(1 to 1)
   10·2
(8·9 to 11·8)
     6·7
(5·8 to 7·7)
   11·0
(9·3 to 12·8)
 –4·2
(–6·0 to –2·5)
   3·3
(2·0 to 4·7)
   0·3
(–0·6 to 1·2)
    Malta           1
(1 to 1)
          0
(0 to 1)
          0
(0 to 0)
   10·5
(9·1 to 12·1)
   10·9
(9·5 to 12·5)
     5·9
(5·1 to 6·9)
   0·4
(–1·5 to 2·1)
 –4·1
(–5·5 to –2·8)
 –2·3
(–3·2 to –1·5)
    Netherlands         23
(20 to 26)
        26
(23 to 29)
        12
(10 to 14)
   12·0
(10·5 to 13·7)
   13·2
(11·7 to 14·9)
     6·7
(5·8 to 7·8)
   1·0
(–0·6 to 2·6)
 –4·5
(–5·8 to –3·3)
 –2·3
(–3·1 to –1·6)
    Norway           4
(3 to 5)
          3
(3 to 4)
          2
(2 to 3)
     6·7
(5·7 to 7·9)
     6·0
(5·1 to 7·0)
     3·8
(3·2 to 4·5)
 –1·2
(–3·2 to 0·9)
 –3·0
(–4·6 to –1·4)
 –2·3
(–3·3 to –1·4)
    Portugal         21
(19 to 24)
        15
(13 to 17)
          7
(6 to 9)
   18·8
(16·7 to 21·3)
   13·3
(11·8 to 14·9)
     9·0
(7·8 to 10·3)
 –3·5
(–5·0 to –2·0)
 –2·6
(–3·7 to –1·4)
 –2·9
(–3·7 to –2·2)
    Spain         50
(45 to 56)
        30
(27 to 34)
        23
(20 to 27)
   12·5
(11·1 to 13·9)
     7·5
(6·7 to 8·4)
     5·6
(4·8 to 6·4)
 –5·1
(–6·6 to –3·7)
 –1·9
(–3·2 to –0·8)
 –3·2
(–3·9 to –2·5)
    Sweden         12
(11 to 13)
          6
(6 to 7)
          5
(5 to 6)
   10·4
(9·6 to 11·4)
     6·8
(6·2 to 7·4)
     4·4
(3·9 to 4·9)
 –4·4
(–5·4 to –3·3)
 –2·9
(–3·9 to –2·0)
 –3·5
(–4·1 to –2·9)
    Switzerland           6
(5 to 7
          6
(5 to 7)
          5
(4 to 6)
     7·1
(6·2 to 8·1)
     7·6
(6·6 to 8·7)
     5·8
(4·9 to 6·8)
   0·7
(–0·9 to 2·4)
 –1·8
(–3·1 to –0·4)
 –0·8
(–1·7 to 0·1)
    UK         85
(80 to 90)
        93
(87 to 99)
        75
(69 to 81)
   10·9
(10·3 to 11·6)
   13·4
(12·5 to 14·2)
     9·2
(8·5 to 10·0)
   2·1
(1·4 to 2·7)
 –2·5
(–3·1 to –1·8)
 –0·7
(–1·1 to –0·3)
      England         68
(64 to 73)
        75
(70 to 80)
        61
(56 to 67)
   10·5
(9·8 to 11·3)
   12·8
(11·9 to 13·7)
     8·8
(8·0 to 9·6)
   1·9
(1·2 to 2·7)
 –2·5
(–3·2 to –1·7)
 –0·7
(–1·2 to –0·3)
      Northern
Ireland
          3
(3 to 4)
          4
(3 to 4)
          3
(3 to 3)
   12·3
(10·8 to 14·1)
   16·0
(14·1 to 18·3)
   11·9
(10·2 to 13·9)
   2·7
(0·9 to 4·2)
 –1·9
(–3·2 to –0·7)
 –0·1
(–1·0 to 0·7)
      Scotland           9
(8 to 10)
        11
(9 to 12)
          7
(6 to 8)
   14·3
(12·5 to 16·2)
   19·4
(17·0 to 22·0)
   13·1
(11·3 to 15·2)
   3·0
(1·5 to 4·7)
 –2·6
(–3·9 to –1·3)
 –0·4
(–1·1 to 0·4)
      Wales           4
(3 to 4)
          4
(4 to 5)
          3
(3 to 4)
   10·0
(8·7 to 11·5)
   12·6
(11·1 to 14·2)
     9·3
(8·0 to 10·9)
   2·3
(0·4 to 3·9)
 –2·0
(–3·3 to –0·6)
 –0·3
(–1·1 to 0·5)
Southern Latin
America
      635
(582 to 693)
      466
(426 to 509)
      435
(385 to 498)
   60·1
(55·2 to 65·6)
   45·3
(41·5 to 49·5)
   42·0
(37·2 to 48·0)
 –2·8
(–4·0 to –1·6)
 –0·5
(–1·5 to 0·6)
 –1·4
(–2·0 to –0·8)
    Argentina       463
(412 to 518)
      390
(351 to 431)
      377
(328 to 438)
   64·9
(57·7 to 72·5)
   54·2
(48·8 to 59·9)
   50·0
(43·6 to 58·1)
 –1·8
(–3·2 to –0·4)
 –0·6
(–1·7 to 0·7)
 –1·1
(–1·7 to –0·3)
    Chile       149
(133 to 164)
        60
(53 to 67)
        48
(41 to 56)
   52·1
(46·8 to 57·5)
   23·6
(21·0 to 26·5)
   20·5
(17·6 to 23·9)  –7·9
*
(–9·3 to –6·4)
 –0·9
(–2·2 to 0·3)
 –3·7
(–4·5 to –3·0)
    Uruguay         23
(20 to 25)
        16
(14 to 18)
        10
(9 to 12)
   39·8
(35·0 to 44·5)
   29·8
(26·4 to 33·4)
   21·3
(18·3 to 24·8)
 –2·9
(–4·3 to –1·3)
 –2·2
(–3·5 to –1·0)
 –2·5
(–3·2 to –1·7)
Central Europe, eastern 
Europe, and central Asia
     3503
(3336 to 3675)
     2023
(1913 to 2142)
     1135
(1032 to 1239)
   52·4
(49·9 to 54·9)
   43·8
(41·4 to 46·4)
   20·3
(18·5 to 22·2)
 –1·8
(–2·4 to –1·1)
 –5·1
(–5·9 to –4·5)
 –3·8
(–4·2 to –3·4)
    Eastern Europe      1570
(1432 to 1705)
      934
(860 to 1 017)
      478
(425 to 539)
   52·9
(48·3 to 57·5)
   48·3
(44·5 to 52·5)
   18·9
(16·8 to 21·3)
 –0·9
(–2·0 to 0·2)  –6·3
*
(–7·3 to –5·3)
 –4·1
(–4·7 to –3·5)
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Number of maternal deaths Maternal mortality ratio (per 100 000 livebirths) Annualised rate of change in maternal 
mortality ratio (%)
1990 2000 2015 1990 2000 2015 1990–2000 2000–15 1990–2015
      Belarus         53
(46 to 61)
        36
(31 to 42)
          9
(7 to 11)
   37·5
(32·5 to 43·1)
   40·7
(35·0 to 47·2)
     7·9
(6·1 to 10·1)
   0·8
(–1·0 to 2·6)  –10·9
*
(–12·9 to –9·0)
 –6·2*
(–7·3 to –5·2)
      Estonia           8
(7 to 9)
          3
(3 to 3)
          1
(1 to 1)
   40·0
(35·1 to 45·4)
   23·4
(20·5 to 26·6)
    4·6
(3·8 to 5·6)
 –5·4
(–7·1 to –3·8)  –10·8
*
(–12·5 to –9·3)
 –8·6*
(–9·6 to –7·7)
      Latvia         17
(15 to 19)
          5
(4 to 6)
          3
(2 to 3)
   47·4
(41·6 to 53·7)
   26·2
(23·0 to 29·8)
   12·6
(10·6 to 14·8)  –5·9
*
(–7·5 to –4·3)
 –4·9
(–6·3 to –3·5)
 –5·3
(–6·1 to –4·5)
      Lithuania         17
(15 to 20)
          5
(5 to 6)
          3
(3 to 3)
   32·0
(28·3 to 36·0)
   15·5
(13·5 to 17·6)
   10·0
(8·5 to 11·6) –7·2
*
(–8·8 to –5·6)
 –2·9
(–4·3 to –1·6)
 –4·7
(–5·4 to –3·9)
      Moldova         39
(34 to 43)
         15
(13 to 17)
          6
(5 to 7)
   48·0
(42·7 to 53·7)
   30·4
(26·6 to 34·6)
   14·4
(12·1 to 17·2)
 –4·5
(–6·1 to –2·9)
 –5·0
(–6·5 to –3·5)
 –4·8
(–5·7 to –4·0)
      Russia      1123
(1003 to 1247)
       655
(587 to 732)
       340
(292 to 398)
   56·1
(50·2 to 62·4)
   49·3
(44·2 to 55·1)
   18·7
(16·0 to 21·8)
 –1·3
(–2·8 to 0·1)  –6·5
*
(–7·8 to –5·2)
 –4·4
(–5·1 to –3·7)
      Ukraine        313
(279 to 348)
       215
(192 to 241)
      116
(96 to 138)
   49·4
(44·0 to 54·9)
   53·3
(47·5 to 59·8)
   24·0
(19·9 to 28·5)
   0·7
(–0·7 to 2·3)
 –5·3
(–6·7 to –3·9)
 –2·9
(–3·8 to –2·0)
  Central Europe       738
(698 to 784)
       245
(230 to 262)
       111
(101 to 119)
   42·6
(40·3 to 45·2)
   20·4
(19·1 to 21·7)
    9·7
(8·8 to 10·4)  –7·4
*
(–8·1 to –6·6)
 –5·0
(–5·7 to –4·3)  –5·9
*
(–6·4 to –5·5)
      Albania          23
(19 to 28)
          8
(7 to 10)
          4
(3 to 5)
   29·3
(23·6 to 35·8)
   15·7
(12·8 to 19·0)
    9·6
(6·8 to 13·1)  –6·2
*
(–8·9 to –3·7)
 –3·3
(–5·9 to –0·7)
 –4·5
(–5·9 to –3·0)
      Bosnia and Herzegovina         23
(19 to 29)
        10
(8 to 14)
          4
(3 to 6)
   36·4
(29·5 to 45·5)
   27·2
(20·4 to 36·1)
    13·2
(10·0 to 17·4)
 –2·9
(–5·9 to 0·1)
 –4·8
(–7·1 to –2·5)
 –4·1
(–5·4 to –2·7)
      Bulgaria         49
(44 to 54)
        35
(31 to 38)
        14
(12 to 16)
   46·4
(42·1 to 51·3)
   53·4
(48·0 to 59·0)
   21·1
(18·2 to 24·1)
   1·4
(0·1 to 2·6)  –6·2
*
(–7·3 to –5·1)
 –3·2
(–3·8 to –2·5)
      Croatia           9
(8 to 10)
          6
(6 to 7)
          4
(3 to 4)
   16·1
(14·3 to 18·2)
   14·0
(12·5 to 15·8)
     9·5
(8·3 to 10·7)
 –1·4
(–2·9 to 0·0)
 –2·6
(–3·9 to –1·5)
 –2·1
(–2·9 to –1·4)
      Czech Republic         22
(20 to 25)
          9
(8 to 10)
         7
(6 to 8)
   17·5
(15·6 to 19·5)
   10·1
(9·0 to 11·2)
     6·2
(5·2 to 7·2)  –5·5
*
(–7·0 to –4·1)
 –3·2
(–4·5 to –2·0)
 –4·1
(–5·0 to –3·4)
      Hungary          24
(21 to 27)
         11
(10 to 12)
          9
(8 to 11)
   19·0
(16·7 to 21·7)
   11·4
(10·0 to 12·9)
   10·0
(8·6 to 11·7)
 –5·2
(–6·8 to –3·5)
 –0·8
(–2·1 to 0·4)
 –2·6
(–3·4 to –1·8)
      Macedonia           6
(5 to 7)
          4
(3 to 4)
          2
(2 to 2)
   16·8
(13·7 to 20·5)
   14·5
(12·5 to 16·8)
     8·3
(6·8 to 10·2)
 –1·5
(–3·7 to 0·7)
 –3·7
(–5·3 to –2·1)
 –2·8
(–4·0 to –1·6)
      Montenegro           1
(1 to 2)
          1
(1 to 2)
          0
(0 to 1)
   11·4
(8·5 to 14·9)
   14·1
(10·7 to 18·4)
     5·7
(4·1 to 8·0)
   2·0
(–1·1 to 5·2)  –5·9
*
(–9·2 to –3·0)
 –2·8
(–4·6 to –0·8)
      Poland       194
(176 to 212)
        49
(44 to 54)
        17
(15 to 20)
   34·0
(30·8 to 37·2)
   13·2
(11·9 to 14·6)
     4·4
(3·9 to 5·1)    –9·4
*
(–10·7 to –8·1)
 –7·3*
(–8·4 to –6·2)
 –8·2*
(–8·8 to –7·5)
      Romania       342
(311 to 377)
        88
(78 to 99)
        34
(28 to 40)
 107·5
(97·7 to 118·4)
   39·6
(35·2 to 44·4)
   18·9
(15·9 to 22·4) –10·0
*
(–11·4 to –8·6)
 –4·9
(–6·4 to –3·5)  –6·9
*
(–7·8 to –6·2)
      Serbia         30
(22 to 44)
        15
(13 to 18)
        10
(8 to 12)
   21·0
(15·2 to 30·7)
   12·6
(10·8 to 14·9)
    11·0
(9·3 to 13·2)
 –4·7
(–9·1 to –1·6)
 –0·9
(–2·4 to 0·8)
 –2·4
(–4·3 to –1·0)
      Slovakia          13
(11 to 16)
          7
(6 to 8)
          4
(3 to 4)
   16·6
(13·8 to 19·6)
   13·2
(11·4 to 15·0)
     6·6
(5·5 to 7·8)
 –2·3
(–4·1 to –0·1)
 –4·6
(–6·0 to –3·2)
 –3·7
(–4·7 to –2·7)
      Slovenia           2
(2 to 3)
          2
(2 to 2)
          1
(1 to 1)
   10·5
(9·2 to 12·2)
   10·6
(9·3 to 12·1)
     5·6
(4·7 to 6·6)
   0·0
(–1·6 to 1·8)
 –4·2
(–5·6 to –2·9)
 –2·5
(–3·4 to –1·7)
  Central Asia      1195
(1111 to 1279)
      844
(785 to 921)
      547
(476 to 616)
   60·0
(55·8 to 64·2)
   57·0
(53·1 to 62·2)
   28·4
(24·8 to 32·0)
 –0·5
(–1·5 to 0·5)
 –4·6
(–5·7 to –3·7)
 –3·0
(–3·6 to –2·5)
      Armenia         37
(32 to 43)
        19
(16 to 22)
          9
(8 to 12)
   49·5
(42·4 to 57·6)
   45·7
(38·7 to 53·0)
   24·1
(19·2 to 29·7)
 –0·8
(–2·9 to 1·4)
 –4·3
(–6·0 to –2·5)
 –2·9
(–3·9 to –1·9)
      Azerbaijan         77
(66 to 90)
        67
(57 to 79)
        38
(29 to 49)
   39·1
(33·4 to 45·5)
   47·6
(40·3 to 55·7)
   19·8
(14·8 to 25·4)
   2·0
(–0·1 to 4·2)  –5·9
*
(–8·2 to –3·8)
 –2·7
(–4·0 to –1·6)
      Georgia         38
(31 to 44)
        17
(15 to 21)
        23
(19 to 28)
   41·5
(34·4 to 48·5)
   30·7
(25·7 to 36·6)
   42·3
(34·6 to 51·7)
 –3·0
(–5·3 to –0·6)
  2·1
(0·3 to 3·9)
   0·1
(–0·9 to 1·1)
      Kazakhstan       243
(217 to 270)
      147
(131 to 164)
      100
(83 to 121)
   63·5
(56·7 to 70·5)
   61·4
(54·6 to 68·4)
   26·5
(22·1 to 32·0)
 –0·3
(–1·8 to 1·1)  –5·6
*
(–7·0 to –4·1)
 –3·5
(–4·3 to –2·6)
      Kyrgyzstan         90
(77 to 104)
        69
(60 to 80)
        74
(60 to 88)
   66·2
(56·5 to 76·5)
   63·9
(55·1 to 73·7)
   47·8
(38·9 to 56·9)
 –0·4
(–2·3 to 1·6)
 –1·9
(–3·5 to –0·4)
 –1·3
(–2·3 to –0·4)
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Number of maternal deaths Maternal mortality ratio (per 100 000 livebirths) Annualised rate of change in maternal 
mortality ratio (%)
1990 2000 2015 1990 2000 2015 1990–2000 2000–15 1990–2015
      Mongolia       119
(97 to 141)
        81
(69 to 96)
        40
(31 to 51)
 171·2
(140·5 to 202·4)
 175·4
(149·3 to 205·9)
   58·3
(45·0 to 73·2)
   0·3
(–2·0 to 2·4)  –7·4
*
(–9·5 to –5·4)
 –4·3
(–5·4 to – 
3·2)
      Tajikistan        151
(130 to 173)
      107
(92 to 126)
        66
(51 to 84)
   71·3
(61·5 to 81·6)
   56·5
(48·1 to 66·0)
   25·6
(19·8 to 32·6)
 –2·4
(–4·2 to –0·3)
 –5·3
(–7·0 to –3·6)
 –4·1
(–5·2 to –3·0)
      Turkmenistan          80
(70 to 92)
        74
(61 to 89)
        22
(18 to 27)
   61·6
(53·4 to 70·5)
   69·3
(56·8 to 83·1)
   19·4
(15·7 to 23·7)
   1·1
(–1·1 to 3·4)  –8·5
*
(–10·1 to –6·8)
 –4·7
(–5·6 to –3·6)
      Uzbekistan       359
(311 to 415)
      262
(223 to 314)
      175
(134 to 219)
   51·6
(44·6 to 59·5)
   47·6
(40·6 to 57·0)
   26·2
(20·1 to 32·8)
 –0·9
(–2·8 to 1·3)
 –4·0
(–6·0 to –2·1)
 –2·7
(–3·8 to –1·6)
Latin America and 
Caribbean
 12 238
(11 695 to 12 
878)
     9690
(9225 to 10 
253)
     7214
(6605 to 8030)
 112·8
(107·8 to 118·7)
  89·7
(85·4 to 94·9)
   73·6
(67·4 to 81·9)
 –2·3
(–2·8 to –1·7)
 –1·3
(–1·9 to –0·6)
 –1·7
(–2·1 to –1·3)
   Central Latin America      4397
(4193 to 4625)
     3512
(3349 to 3668)
     2611
(2421 to 2803)
   89·0
(84·9 to 93·6)
   71·1
(67·8 to 74·2)
   55·9
(51·8 to 60·0)
 –2·2
(–2·7 to –1·8)
 –1·6
(–2·2 to –1·1)
 –1·9
(–2·2 to –1·5)
      Colombia       933
(806 to 1 086)
      703
(637 to 773)
      402
(344 to 459)
 103·0
(89·2 to 119·9)
   82·9
(75·2 to 91·2)
   53·8
(46·1 to 61·5)
 –2·1
(–3·7 to –0·6)
 –2·9
(–4·1 to –1·7)
 –2·6
(–3·3 to –1·8)
       Costa Rica         24
(21 to 27)
        27
(24 to 30)
        17
(14 to 20)
   29·6
(25·9 to 33·2)
   34·9
(30·9 to 39·4)
   24·3
(20·6 to 28·2)
   1·6
(0·2 to 3·2)
 –2·4
(–3·7 to –1·1)
 –0·8
(–1·6 to 0·0)
      El Salvador       228
(197 to 263)
        72
(61 to 86)
        40
(31 to 52)
 140·2
(121·4 to 161·9)
   51·8
(44·0 to 61·3)
   38·3
(29·2 to 49·3) –10·0
*
(–12·1 to –7·8)
 –2·1
(–4·1 to 0·1)
 –5·2
(–6·4 to –4·1)
      Guatemala       516
(454 to 587)
      433
(389 to 483)
      320
(228 to 417)
 146·2
(129·2 to 166·0)
 106·5
(95·5 to 118·5)
   73·2
(52·1 to 95·0)
 –3·1
(–4·8 to –1·7)
 –2·6
(–4·8 to –0·6)
 –2·8
(–4·2 to –1·6)
      Honduras       330
(281 to 381)
      238
(172 to 319)
      185
(119 to 274)
 175·4
(149·3 to 202·5)
 120·7
(87·5 to 161·7)
 109·6
(70·3 to 162·1)
 –3·8
(–6·9 to –0·7)
 –0·7
(–3·5 to 2·1)
 –2·0
(–3·7 to –0·3)
      Mexico      1804
(1709 to 1912)
     1518
(1428 to 1610)
     1131
(1057 to 1206)
   73·3
(69·5 to 77·7)
   61·1
(57·5 to 64·8)
   48·2
(45·1 to 51·4)
 –1·8
(–2·2 to –1·4)
 –1·6
(–2·2 to –1·0)
 –1·7
(–2·0 to –1·3)
      Nicaragua       130
(111 to 152)
      136
(117 to 160)
        83
(65 to 106)
   87·4
(74·5 to 102·3)
 101·0
(86·4 to 118·7)
   68·8
(53·7 to 87·3)
   1·4
(–0·7 to 3·7)
 –2·6
(–4·4 to –0·7)
 –1·0
(–2·2 to 0·1)
      Panama         44
(37 to 53)
        45
(39 to 53)
        52
(41 to 65)
   68·7
(56·7 to 82·3)
   64·2
(55·1 to 75·7)
   69·4
(54·8 to 86·2)
 –0·7
(–2·7 to 1·5)
   0·5
(–1·3 to 2·4)
   0·0
(–1·1 to 1·2)
      Venezuela       388
(348 to 426)
      339
(305 to 374)
      381
(298 to 467)
   67·2
(60·4 to 74·0)
   58·3
(52·5 to 64·4)
   63·5
(49·8 to 77·8)
 –1·4
(–2·8 to –0·1)
  0·6
(–1·2 to 2·2)
 –0·2
(–1·3 to 0·8)
   Andean Latin America      2504
(2250 to 2800)
     1450
(1319 to 1583)
      825
(674 to 985)
 206·7
(185·8 to 230·9)
 121·2
(110·2 to 132·2)
  68·8
(56·2 to 82·2)
 –5·3
(–6·7 to –4·1)
 –3·8
(–5·2 to –2·4)
 –4·4
(–5·4 to –3·6)
      Bolivia       941
(756 to 1 169)
      535
(448 to 628)
      366
(259 to 508)
 387·0
(311·1 to 480·7)
 207·5
(174·2 to 243·6)
 144·5
(102·4 to 200·8)  –6·1
*
(–8·5 to –3·9)
 –2·4
(–5·0 to 0·0)
 –3·9
(–5·7 to –2·4)
      Ecuador       381
(332 to 432)
      231
(197 to 266)
      170
(136 to 212)
 123·7
(108·0 to 140·4)
   73·4
(62·8 to 84·7)
  51·3
(41·0 to 63·9)
 –5·3
(–7·0 to –3·2)
 –2·4
(–4·1 to –0·7)
 –3·5
(–4·6 to –2·4)
      Peru      1182
(997 to 1 406)
      685
(598 to 779)
      290
(218 to 363)
 179·0
(151·0 to 212·8)
 109·7
(95·8 to 124·6)
   47·1
(35·5 to 59·0)
 –4·9
(–6·9 to –2·8)  –5·6
*
(–7·6 to –3·9)
 –5·3
(–6·6 to –4·2)
   Caribbean      2048
(1713 to 2590)
     1959
(1632 to 2468)
     1664
(1155 to 2430)
 234·4
(196·4 to 294·7)
 240·3
(200·9 to 301·2)
 219·7
(152·5 to 319·4)
   0·2
(–2·0 to 2·8)
 –0·8
(–3·0 to 1·9)
 –0·3
(–1·7 to 1·3)
      Antigua and Barbuda           1
(1 to 1)
          1
(1 to 1)
          1
(0 to 1)
   54·0
(45·7 to 64·6)
   50·7
(42·0 to 60·9)
   37·2
(31·1 to 45·0)
 –0·6
(–3·1 to 1·5)
 –2·1
(–3·7 to –0·4)
 –1·5
(–2·5 to –0·6)
      The Bahamas           5
(4 to 6)
          4
(3 to 5)
          3
(2 to 4)
   73·6
(58·9 to 90·5)
   74·6
(60·9 to 90·9)
   50·4
(37·2 to 63·8)
   0·2
(–2·6 to 2·9)
 –2·6
(–4·7 to –0·5)
 –1·5
(–2·9 to –0·2)
      Barbados           3
(3 to 4)
          1
(1 to 2)
          1
(1 to 2)
   83·8
(72·1 to 95·7)
   34·8
(29·2 to 41·0)
   38·9
(30·5 to 49·2)  –8·8
*
(–10·9 to –6·6)
   0·7
(–1·3 to 2·7)
 –3·1
(–4·2 to –2·0)
      Belize           3
(3 to 4)
          5
(4 to 5)
          3
(2 to 3)
   47·7
(39·4 to 57·0)
   62·1
(51·7 to 74·5)
   32·2
(25·2 to 41·4)
   2·6
(0·3 to 5·0)
 –4·4
(–6·3 to –2·5)
 –1·6
(–2·7 to –0·4)
      Bermuda           0
(0 to 0)
          0
(0 to 0)
          0
(0 to 0)
    4·6
(3·9 to 5·5)
    3·0
(2·3 to 3·7)
    2·3
(1·8 to 2·9)
 –4·5
(–7·2 to –1·8)
 –1·7
(–3·8 to 0·6)
 –2·8
(–4·0 to –1·6)
      Cuba         91
(80 to 103)
        75
(67 to 85)
        48
(41 to 55)
   51·3
(45·5 to 58·1)
   51·5
(45·8 to 58·2)
   41·7
(35·8 to 48·3)
   0·0
(–1·5 to 1·7)
 –1·4
(–2·6 to –0·2)
 –0·9
(–1·6 to 0·0)
      Dominica           0
(0 to 0)
          0
(0 to 0)
          0
(0 to 1)
   22·5
(18·5 to 27·3)
   19·4
(15·8 to 23·7)
   38·6
(30·2 to 49·0)
 –1·5
(–4·2 to 1·0)
   4·6
(2·5 to 6·5)
   2·2
(0·9 to 3·3)
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Number of maternal deaths Maternal mortality ratio (per 100 000 livebirths) Annualised rate of change in maternal 
mortality ratio (%)
1990 2000 2015 1990 2000 2015 1990–2000 2000–15 1990–2015
      Dominican Republic       196
(168 to 226)
      130
(114 to 149)
      116
(92 to 144)
   91·3
(78·4 to 105·6)
   60·3
(52·7 to 69·0)
   53·6
(42·8 to 66·8)
 –4·1
(–6·2 to –2·2)
 –0·8
(–2·5 to 1·0)
 –2·2
(–3·2 to –1·0)
      Grenada           1
(1 to 2)
          1
(1 to 1)
          1
(1 to 1)
   51·8
(42·5 to 61·9)
   30·1
(25·6 to 36·3)
   34·0
(26·9 to 42·7)
 –5·4
(–7·7 to –3·1)
   0·8
(–1·0 to 2·8)
 –1·7
(–3·0 to –0·5)
      Guyana          32
(27 to 37)
         30
(26 to 37)
         16
(12 to 21)
 132·6
(111·8 to 154·9)
 160·7
(134·9 to 194·2)
 108·7
(80·5 to 140·6)
   1·8
(–0·3 to 4·2)
 –2·6
(–4·7 to –0·6)
 –0·8
(–2·1 to 0·4)
      Haiti      1565
(1249 to 2062)
     1564
(1247 to 2048)
     1371
(880 to 2113)
 591·6
(472·5 to 776·8)
 587·9
(469·2 to 768·1)
 520·8
(334·5 to 802·1)
 –0·1
(–2·7 to 2·9)
 –1·0
(–3·6 to 2·1)
 –0·6
(–2·2 to 1·3)
      Jamaica          25
(20 to 32)
         37
(29 to 45)
         24
(18 to 32)
   41·1
(32·7 to 51·4)
   66·0
(52·9 to 81·4)
   50·3
(36·4 to 66·7)
   4·8
(1·8 to 7·6)
 –1·8
(–4·2 to 0·5)
   0·8
(–0·7 to 2·3)
      Puerto Rico          19
(16 to 21)
         14
(12 to 16)
          7
(5 to 8)
   29·6
(25·9 to 33·4)
   25·7
(22·8 to 28·9)
   15·1
(12·7 to 17·8)
 –1·4
(–3·0 to 0·3)
 –3·6
(–4·9 to –2·2)
 –2·7
(–3·6 to –1·8)
      Saint Lucia           2
(2 to 3)
          3
(2 to 3)
          2
(1 to 2)
   54·7
(46·7 to 64·2)
   84·2
(72·2 to 96·4)
   59·8
(47·7 to 73·9)
   4·3
(2·3 to 6·3)
 –2·3
(–4·0 to –0·5)
   0·3
(–0·7 to 1·5)
      Saint Vincent and the 
Grenadines
          1
(1 to 2)
          1
(1 to 1)
          1
(1 to 1)
   54·9
(43·9 to 68·1)
   33·9
(29·2 to 39·7)
   40·5
(33·0 to 49·1)
 –4·8
(–7·5 to –2·0)
   1·2
(–0·6 to 2·8)
 –1·2
(–2·4 to –0·1)
      Suriname           7
(6 to 8)
          9
(8 to 11)
          5
(4 to 6)
   62·3
(50·8 to 74·9)
   86·4
(72·5 to 103·1)
   51·5
(39·4 to 66·2)
   3·3
(0·8 to 5·7)
 –3·5
(–5·3 to –1·5)
 –0·8
(–2·1 to 0·6)
      Trinidad and Tobago          19
(17 to 21)
         11
(10 to 13)
           9
(7 to 12)
   75·2
(66·5 to 84·6)
   60·8
(53·0 to 69·2)
   49·4
(38·8 to 62·1)
 –2·1
(–3·8 to –0·5)
 –1·4
(–3·2 to 0·5)
 –1·7
(–2·7 to –0·6)
      Virgin Islands           1
(1 to 1)
          0
(0 to 0)
          0
(0 to 0)
   30·0
(24·6 to 36·9)
   21·6
(18·0 to 25·8)
   10·9
(8·6 to 13·6)
 –3·3
(–5·8 to –0·9)
 –4·6
(–6·6 to –2·6)
 –4·1
(–5·3 to –2·8)
   Tropical Latin America      3290
(3097 to 3509)
     2769
(2613 to 2933)
     2113
(1918 to 2313)
   86·9
(81·8 to 92·7)
   72·5
(68·4 to 76·8)
   67·0
(60·8 to 73·2)
 –1·8
(–2·6 to –1·0)
 –0·5
(–1·2 to 0·1)
 –1·0
(–1·5 to –0·6)
      Brazil      3081
(2896 to 3299)
     2610
(2459 to 2778)
     1972
(1786 to 2165)
   84·5
(79·4 to 90·4)
   71·0
(66·9 to 75·5)
   65·4
(59·2 to 71·8)
 –1·7
(–2·5 to –0·9)
 –0·6
(–1·3 to 0·2)
 –1·0
(–1·5 to –0·5)
      Paraguay       209
(177 to 244)
      159
(136 to 186)
      141
(102 to 185)
 147·9
(124·9 to 172·1)
 110·6
(95·2 to 129·3)
 100·6
(72·8 to 131·7)
 –2·9
(–5·2 to –0·7)
 –0·7
(–3·1 to 1·5)
 –1·6
(–3·0 to –0·3)
Southeast Asia, east Asia, 
and Oceania
  67 636
(59 318 to 76 
231)
  45 834
(39 712 to 53 
353)
  20 424
(16 922 to 25 
379)
 170·8
(149·8 to 192·4)
 161·1
(139·7 to 187·5)
   68·9
(57·1 to 85·5)
 –0·6
(–1·8 to 0·8)  –5·7
*
(–7·1 to –4·1)
 –3·7
(–4·5 to –2·7)
   East Asia   30 419
(26 086 to 35 
170)
  13 780
(12 296 to 15 
438)
     3236
(2767 to 3714)
 112·8
(96·8 to 130·5)
   84·2
(75·1 to 94·3)
   18·8
(16·0 to 21·5)
 –3·0
(–4·5 to –1·2)  –10·0
*
(–11·3 to –8·7)
 –7·2*
(–8·0 to –6·4)
      China   29 922
(25 545 to 34 
638)
  13 344
(11 932 to 14 
962)
     2948
(2501 to 3426)
 114·2
(97·6 to 132·1)
   85·2
(76·2 to 95·6)
   17·7
(15·0 to 20·5)
 –3·0
(–4·5 to –1·1)  –10·5
*
(–11·9 to –9·1)
 –7·5*
(–8·3 to –6·6)
      North Korea       426
(240 to 725)
      390
(222 to 637)
      263
(155 to 409)
 101·3
(57·2 to 171·5)
   95·3
(54·3 to 155·1)
   73·0
(43·2 to 113·4)
 –0·5
(–7·0 to 5·1)
 –1·7
(–6·2 to 2·7)
 –1·3
(–4·1 to 1·6)
      Taiwan         71
(46 to 104)
        46
(32 to 64)
        25
(16 to 36)
   21·1
(13·7 to 30·7)
   15·1
(10·4 to 20·9)
   11·5
(7·5 to 16·8)
 –3·3
(–7·0 to 0·3)
 –1·8
(–5·4 to 1·8)
 –2·5
(–4·7 to 0·1)
   Southeast Asia   36 261
(30 495 to 43 
464)
  30 895
(25 298 to 38 
353)
  16 112
(12 578 to 21 
203)
 292·2
(245·9 to 350·0)
 262·1
(214·6 to 325·1)
 133·4
(104·2 to 175·3)
 –1·1
(–2·7 to 0·6)
 –4·5
(–6·3 to –2·4)
 –3·1
(–4·3 to –1·9)
      Cambodia      1493
(1247 to 1779)
     1502
(1263 to 1799)
      485
(322 to 710)
 388·6
(324·8 to 462·8)
 440·2
(370·3 to 527·2)
 130·8
(86·9 to 191·3)
   1·2
(–0·7 to 3·3)  –8·1
*
(–11·2 to –5·3)
 –4·4
(–6·2 to –2·8)
      Indonesia   18 715
(15 508 to 21 
799)
  15 726
(13 450 to 18 
578)
     8937
(6104 to 12 
557)
 399·4
(331·1 to 464·8)
 345·3
(295·4 to 407·8)
 177·1
(121·0 to 248·6)
 –1·5
(–3·5 to 0·7)
 –4·6
(–7·2 to –1·9)
 –3·3
(–4·9 to –1·8)
      Laos      1193
(853 to 1 582)
     1002
(800 to 1 293)
      420
(296 to 574)
 652·7
(467·4 to 863·2)
 589·1
(470·8 to 759·9)
 234·4
(165·6 to 320·6)
 –1·0
(–3·5 to 1·8)  –6·2
*
(–8·9 to –3·8)
 –4·1
(–5·8 to –2·4)
      Malaysia        450
(385 to 529)
         369
(325 to 421)
      313
(233 to 410)
   87·6
(74·9 to 102·9)
   70·2
(61·8 to 80·1)
   61·5
(45·8 to 80·0)
 –2·2
(–4·0 to –0·5)
 –0·9
(–3·0 to 1·2)
 –1·4
(–2·8 to –0·2)
      Maldives         17
(12 to 24)
            6
(5 to 7)
          3
(2 to 4)
 185·5
(136·3 to 263·4)
   93·4
(74·9 to 115·7)
   40·9
(27·7 to 56·7)  –6·7
*
(–10·1 to –3·9)
 –5·5*
(–8·4 to –2·9)
 –5·9*
(–8·6 to –4·2)
      Mauritius         15
(13 to 17)
            8
(7 to 10)
           7
(6 to 8)
   67·3
(59·2 to 76·2)
   42·2
(37·3 to 47·9)
   49·6
(41·9 to 58·4)
 –4·7
(–6·3 to –3·1)
   1·1
(–0·3 to 2·5)
 –1·2
(–2·1 to –0·4)
      Myanmar   10 284      9503      3691
(1969 to 6476)
 909·3
(519·3 to 1478·1)
 820·8
(436·9 to 1415·5)
 391·2
(208·7 to 685·9)
 –1·1
(–5·4 to 3·2)
 –5·0
(–8·8 to –1·0)
 –3·5
(–5·9 to –0·6)
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(5857 to 16 
737)
(5027 to 16 
391)
      Philippines      2208
(1906 to 2518)
     1636
(1499 to 1804)
     1637
(1319 to 1996)
 107·9
(93·2 to 123·1)
   70·7
(64·8 to 77·8)
   69·7
(56·2 to 85·0)
 –4·2
(–5·8 to –2·6)
 –0·1
(–1·7 to 1·3)
 –1·8
(–2·8 to –0·7)
      Sri Lanka       269
(223 to 324)
      222
(196 to 253)
      107
(70 to 155)
   75·2
(62·6 to 90·6)
   63·8
(56·4 to 72·7)
   33·1
(21·8 to 48·0)
 –1·6
(–3·7 to 0·3)
 –4·5
(–7·2 to –1·9)
 –3·3
(–5·1 to –1·6)
      Seychelles           1
(1 to 1)
          1
(0 to 1)
          1
(0 to 1)
   60·5
(46·6 to 75·8)
   38·7
(30·9 to 49·5)
   32·3
(24·5 to 43·1)
 –4·5
(–7·3 to –1·3)
 –1·2
(–3·6 to 1·1)
 –2·5
(–3·9 to –1·0)
      Thailand       438
(362 to 525)
      271
(207 to 344)
      143
(86 to 211)
   40·5
(33·5 to 48·6)
   29·9
(22·9 to 37·9)
   20·0
(12·1 to 29·6)
 –3·1
(–6·2 to –0·2)
 –2·7
(–5·8 to 0·2)
 –2·9
(–4·9 to –1·1)
      Timor-Leste       209
(141 to 277)
      152
(99 to 190)
      104
(64 to 144)
 641·3
(433·1 to 847·1)
 406·1
(264·7 to 505·3)
 236·3
(145·9 to 328·5)
 –4·5
(–9·0 to –0·3)
 –3·7
(–6·6 to –0·7)
 –3·9
(–6·3 to –2·0)
      Vietnam       916
(590 to 1 290)
      452
(311 to 630)
      247
(147 to 387)
   46·7
(30·2 to 65·8)
   32·1
(22·1 to 44·6)
   15·6
(9·4 to 24·4)
 –3·7
(–8·2 to 0·9)
 –4·9
(–8·9 to –1·0)
 –4·4
(–6·8 to –1·8)
    Oceania       957
(606 to 1449)
     1159
(685 to 1814)
     1076
(624 to 1784)
 460·6
(292·2 to 697·1)
 463·6
(274·2 to 722·5)
 386·8
(225·1 to 640·6)
 –0·1
(–3·3 to 3·8)
 –1·3
(–4·4 to 2·3)
 –0·8
(–3·0 to 1·8)
      American Samoa           1
(1 to 1)
          1
(1 to 1)
          1
(1 to 2)
   42·2
(30·5 to 57·9)
   59·9
(46·0 to 74·5)
   57·9
(41·0 to 79·5)
   3·5
(–0·3 to 7·1)
 –0·3
(–3·0 to 2·3)
   1·3
(–0·7 to 3·1)
      Federated States of 
Micronesia
          4
(2 to 8)
          4
(2 to 7)
          2
(1 to 4)
 132·7
(64·0 to 232·8)
 118·1
(50·8 to 220·4)
   88·2
(45·4 to 167·4)
 –1·3
(–6·8 to 3·9)
 –2·0
(–6·1 to 2·8)
 –1·7
(–4·8 to 1·6)
      Fiji         20
(14 to 29)
        23
(18 to 29)
        17
(12 to 24)
   96·2
(65·8 to 133·9)
 114·9
(88·1 to 143·3)
   98·8
(67·4 to 135·7)
   1·9
(–2·2 to 6·0)
 –1·1
(–3·9 to 1·8)
   0·1
(–1·8 to 2·1)
      Guam           1
(1 to 1)
          1
(1 to 1)
          1
(1 to 2)
   21·4
(16·2 to 27·9)
   22·2
(16·9 to 28·4)
   43·0
(29·9 to 60·9)
   0·4
(–3·4 to 4·1)
   4·3
(1·3 to 7·2)
   2·8
(0·8 to 4·5)
      Kiribati           7
(5 to 9)
          4
(3 to 6)
          4
(3 to 6)
 250·5
(189·2 to 326·7)
 171·3
(128·5 to 220·4)
 131·2
(86·9 to 188·4)
 –3·8
(–7·0 to –0·5)
 –1·9
(–4·7 to 0·9)
 –2·7
(–4·4 to –0·6)
      Marshall Islands           2
(1 to 3)
          2
(1 to 3)
          2
(1 to 3)
 112·4
(80·1 to 156·0)
 126·6
(63·5 to 187·3)
 108·7
(70·0 to 165·8)
   1·2
(–3·1 to 4·9)
 –1·1
(–4·0 to 2·9)
 –0·2
(–2·1 to 2·0)
      Northern Mariana Islands           1
(1 to 1)
          1
(0 to 1)
          1
(1 to 1)
   78·9
(56·3 to 109·2)
   48·7
(37·2 to 62·6)
   59·5
(42·2 to 80·6)
 –4·7
(–8·3 to –1·2)
   1·3
(–1·5 to 3·9)
 –1·1
(–3·1 to 0·7)
      Papua New Guinea       787
(466 to 1241)
      972
(541 to 1558)
      933
(511 to 1607)
 538·1
(318·8 to 848·6)
 519·5
(290·2 to 832·7)
 434·6
(238·2 to 748·4)
 –0·5
(–4·2 to 3·7)
 –1·3
(–4·7 to 2·7)
 –0·9
(–3·4 to 1·8)
      Samoa           4
(2 to 5)
          3
(2 to 5)
          3
(2 to 4)
   65·0
(38·1 to 101·2)
   60·8
(30·1 to 96·0)
   55·2
(32·0 to 83·9)
 –0·6
(–6·9 to 3·6)
 –0·7
(–4·1 to 3·7)
 –0·6
(–3·1 to 1·9)
      Solomon Islands         33
(17 to 54)
        34
(17 to 59)
        35
(17 to 63)
 263·5
(134·3 to 434·0)
 232·9
(117·2 to 402·7)
 207·2
(102·0 to 369·1)
 –1·2
(–6·5 to 3·4)
 –0·8
(–4·7 to 3·7)
 –1·0
(–3·7 to 2·1)
      Tonga           6
(4 to 8)
          5
(4 to 6)
          3
(2 to 5)
 197·6
(135·8 to 278·9)
 187·2
(148·6 to 231·2)
 129·9
(84·1 to 192·4)
 –0·4
(–4·0 to 3·0)
 –2·6
(–5·5 to 0·5)
 –1·7
(–4·0 to 0·3)
      Vanuatu          11
(5 to 19)
        12
(5 to 22)
        12
(6 to 21)
 202·1
(102·6 to 350·5)
 202·0
(78·1 to 359·7)
 172·0
(92·0 to 309·6)
 –0·1
(–6·3 to 5·1)
 –1·2
(–5·0 to 4·3)
 –0·8
(–3·3 to 2·6)
    North Africa and Middle 
East
  22 342
(19 092 to 26 
906)
  20 772
(16 769 to 26 
243)
  19 066
(14 475 to 25 
599)
 197·8
(169·2 to 238·2)
 188·0
(151·8 to 236·6)
 142·3
(108·2 to 190·7)
 –0·5
(–2·3 to 1·1)
 –1·9
(–3·7 to –0·1)
 –1·3
(–2·4 to –0·3)
      North Africa and 
Middle East
  22 342
(19 092 to 26 
906)
  20 772
(16 769 to 26 
243)
  19 066
(14 475 to 25 
599)
 198·0
(169·3 to 238·4)
 188·1
(151·9 to 236·8)
 142·4
(108·3 to 190·9)
 –0·5
(–2·3 to 1·1)
 –1·9
(–3·7 to –0·1)
 –1·3
(–2·4 to –0·3)
      Afghanistan      4590
(2825 to 7111)
     7328
(4529 to 11 
007)
     8525
(5010 to 13 
221)
 732·3
(451·0 to 1130·9)
 753·3
(466·5 to 1130·7)
 788·9
(464·1 to 1219·2)
   0·4
(–4·8 to 5·0)
   0·3
(–3·6 to 3·8)
   0·3
(–2·1 to 2·7)
      Algeria      1275
(977 to 1 583)
      756
(591 to 945)
      626
(466 to 809)
 153·2
(117·5 to 190·1)
 123·9
(96·9 to 154·8)
   66·9
(49·8 to 86·4)
 –2·2
(–5·1 to 0·7)
 –4·1
(–6·6 to –1·6)
 –3·3
(–4·8 to –1·8)
      Bahrain           8
(6 to 11)
          5
(4 to 7)
          5
(4 to 7)
   53·6
(39·9 to 73·5)
   35·6
(27·3 to 47·3)
   24·6
(18·3 to 35·4)
 –4·0
(–7·9 to –0·6)
 –2·5
(–5·1 to 0·4)
 –3·1
(–4·9 to –1·3)
      Egypt      2744
(2308 to 3176)
     1186
(976 to 1414)
     1052
(809 to 1340)
 146·7
(123·4 to 169·7)
   69·2
(57·0 to 82·5)
   42·3
(32·5 to 53·9)  –7·5
*
(–9·7 to –5·5)
 –3·3
(–5·3 to –1·2)
 –5·0
(–6·1 to –3·7)
      Iran      1039
(704 to 1432)
      426
(337 to 539)
      281
(192 to 421)
   56·6
(38·5 to 78·0)
   34·5
(27·3 to 43·7)
   20·8
(14·2 to 31·1)
 –5·0
(–8·6 to –0·6)
 –3·5
(–6·4 to –0·2)
 –4·1
(–6·0 to –1·9)
      Iraq        969
(702 to 1300)
      950
(655 to 1311)
      729
(428 to 1199)
 146·0
(105·9 to 195·9)
 113·4
(78·3 to 156·4)
   58·6
(34·4 to 96·1)
 –2·5
(–6·7 to 1·4)
 –4·5
(–8·2 to –1·0)
 –3·7
(–6·0 to –1·3)
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      Jordan        116
(89 to 149)
      121
(88 to 159)
        48
(36 to 63)
   97·9
(74·6 to 125·4)
   81·2
(58·7 to 106·2)
   24·2
(17·9 to 31·5)
 –1·9
(–5·1 to 1·1)  –8·0
*
(–10·7 to –5·4)
 –5·6*
(–7·2 to –4·1)
      Kuwait           4
(3 to 5)
          5
(4 to 6)
          4
(3 to 6)
     9·7
(8·1 to 11·8)
   11·9
(10·4 to 13·5)
     5·9
(4·4 to 7·5)
   2·1
(0·0 to 4·1)
 –4·8
(–6·8 to –2·8)
 –2·0
(–3·4 to –0·7)
      Lebanon         24
(15 to 38)
        17
(11 to 24)
        13
(8 to 21)
   35·6
(22·8 to 55·1)
   26·7
(18·0 to 39·0)
   15·3
(9·0 to 24·0)
 –2·9
(–7·6 to 1·6)
 –3·9
(–7·6 to 0·3)
 –3·3
(–6·2 to –0·7)
      Libya         34
(24 to 45)
        28
(20 to 37)
        30
(20 to 43)
   26·6
(19·1 to 36·0)
   23·9
(17·2 to 31·5)
   22·8
(15·6 to 32·9)
 –1·0
(–4·8 to 2·3)
 –0·3
(–3·5 to 2·8)
 –0·6
(–2·6 to 1·3)
      Morocco      2441
(1891 to 3201)
     1197
(894 to 1560)
      479
(299 to 756)
 332·7
(258·7 to 436·1)
 192·0
(143·4 to 249·6)
   68·5
(42·8 to 108·1)
 –5·4
(–8·8 to –2·4)  –7·0
*
(–10·1 to –3·4)
 –6·4*
(–8·6 to –4·3)
      Palestine         29
(19 to 43)
        17
(14 to 21)
        25
(17 to 35)
   29·3
(19·0 to 43·7)
   14·2
(11·3 to 17·8)
   16·2
(11·5 to 23·2)  –7·1
*
(–11·2 to –3·1)
   0·8
(–1·9 to 3·9)
 –2·4
(–4·7 to 0·2)
      Oman         24
(14 to 38)
        12
(8 to 18)
        13
(9 to 18)
   34·1
(20·0 to 54·8)
   21·4
(14·8 to 31·7)
   15·5
(11·0 to 21·6)
 –4·5
(–8·7 to –0·3)
 –2·2
(–5·5 to 1·2)
 –3·1
(–5·6 to –0·7)
      Qatar           7
(4 to 10)
          7
(5 to 10)
          7
(4 to 9)
   64·0
(42·0 to 91·5)
   59·9
(41·4 to 84·2)
   25·5
(16·4 to 35·7)
 –0·6
(–4·6 to 3·6)  –5·7
*
(–9·5 to –2·4)
 –3·7
(–6·0 to –1·6)
      Saudi Arabia       124
(93 to 162)
      101
(86 to 119)
        97
(82 to 115)
   21·3
(16·0 to 27·9)
   17·9
(15·2 to 21·0)
   15·7
(13·3 to 18·5)
 –1·6
(–4·0 to 0·6)
 –0·9
(–2·4 to 0·6)
 –1·2
(–2·5 to 0·1)
      Sudan      4131
(2736 to 5570)
     4653
(2790 to 6731)
     3941
(2098 to 5999)
 485·5
(321·7 to 654·4)
 414·4
(248·7 to 598·0)
 298·8
(159·2 to 454·7)
 –1·5
(–5·7 to 1·9)
 –2·3
(–5·5 to 1·0)
 –2·0
(–4·3 to 0·1)
      Syria       560
(421 to 719)
      365
(276 to 480)
      237
(181 to 309)
 125·7
(94·6 to 161·6)
   73·6
(55·6 to 96·7)
   54·1
(41·3 to 70·5)
 –5·3
(–8·1 to –2·6)
 –2·0
(–4·7 to 0·5)
 –3·4
(–5·0 to –1·8)
      Tunisia       183
(143 to 231)
        99
(74 to 126)
        82
(54 to 115)
   85·6
(66·9 to 108·0)
   59·2
(44·3 to 75·2)
   40·6
(26·6 to 56·9)
 –3·7
(–6·6 to –0·8)
 –2·6
(–5·5 to 0·2)
 –3·0
(–4·9 to –1·4)
      Turkey      1453
(1057 to 1985)
      659
(510 to 847)
      204
(162 to 255)
 103·3
(75·4 to 141·2)
   48·2
(37·4 to 61·8)
   15·8
(12·6 to 19·8)  –7·6
*
(–10·9 to –4·4)
 –7·4*
(–9·7 to –5·1)
 –7·5*
(–9·1 to –5·9)
      United Arab Emirates         15
(9 to 23)
        12
(9 to 17)
        18
(11 to 28)
   31·8
(19·9 to 48·8)
   24·0
(17·0 to 32·4)
   18·0
(10·7 to 28·3)
 –2·6
(–7·3 to 2·0)
 –2·0
(–6·1 to 2·0)
 –2·3
(–5·3 to 0·4)
      Yemen      2559
(1342 to 3890)
     2810
(1509 to 4648)
     2631
(1402 to 5009)
 402·6
(211·8 to 611·4)
 399·6
(215·7 to 659·8)
 307·4
(164·5 to 583·8)
 –0·3
(–4·1 to 4·5)
 –1·9
(–5·5 to 2·1)
 –1·3
(–3·7 to 1·8)
    South Asia 174 943
(161 508 to 
189 038)
157 525
(145 824 to 
170 598)
  92 416
(81 008 to 108 
680)
 482·5
(445·5 to 521·3)
 429·2
(397·3 to 464·7)
 264·3
(231·8 to 310·3)
 –1·2
(–1·9 to –0·4)
 –3·3
(–4·1 to –2·2)
 –2·4
–2·9 to –1·8)
      Bangladesh   21 789
(18 195 to 25 
380)
  16 597
(13 124 to 20 
017)
     7663
(5584 to 10 
226)
 581·7
(485·8 to 676·7)
 457·6
(362·0 to 551·3)
 244·5
(178·4 to 325·8)
 –2·4
(–4·6 to –0·3)
 –4·3
(–6·5 to –1·7)
 –3·5
(–4·8 to –2·1)
      Bhutan         96
(61 to 132)
        54
(36 to 76)
        31
(19 to 48)
 490·9
(312·6 to 673·8)
 346·7
(231·4 to 485·9)
 230·3
(138·0 to 354·0)
 –3·5
(–7·0 to 0·1)
 –2·8
(–6·0 to 0·5)
 –3·1
(–5·2 to –0·7)
      India 132 239
(120 991 to 
144 659)
116 206
(106 519 to 
127 563)
  63 861
(55 155 to 77 
388)
 482·1
(441·1 to 526·9)
 416·7
(382·1 to 457·3)
 247·6
(214·0 to 299·9)
 –1·4
(–2·3 to –0·6)
 –3·5
(–4·5 to –2·3)
 –2·7
(–3·3 to –1·9)
      Nepal      3846
(2663 to 4994)
     2630
(1 926 to 3 
360)
     1856
(1170 to 2725)
 528·9
(366·2 to 686·0)
 345·8
(253·5 to 441·7)
 321·6
(203·1 to 472·0)
 –4·3
(–7·2 to –0·8)
 –0·5
(–3·3 to 2·0)
 –2·0
(–4·0 to 0·0)
      Pakistan   16 973
(13 060 to 21 
189)
  22 038
(17 789 to 26 
598)
  19 005
(14 012 to 24 
369)
 391·5
(301·3 to 488·4)
 498·9
(404·1 to 601·7)
 348·6
(257·2 to 447·0)
   2·4
(–0·3 to 5·5)
 –2·4
(–4·7 to –0·3)
 –0·5
(–1·9 to 0·9)
    Sub-Saharan Africa 107 200
(91 543 to 125 
722)
136 629
(120 361 to 
154 268)
133 043
(106 996 to 
168 218)
 495·2
(422·9 to 580·5)
 510·0
(449·6 to 575·7)
 374·9
(301·8 to 473·1)
   0·3
(–1·4 to 2·0)
 –2·1
(–3·6 to –0·4)
 –1·1
(–2·2 to 0·0)
      Southern Sub-Saharan Africa     2720
(2306 to 3138)
     3855
(3091 to 5155)
     3964
(2738 to 6233)
 170·4
(144·5 to 196·6)
 230·5
(184·9 to 307·8)
 211·3
(146·0 to 332·3)
   2·8
(0·6 to 6·0)
 –0·7
(–3·4 to 2·4)
   0·7
(–0·6 to 2·6)
       Botswana         74
(18 to 220)
      193
(35 to 815)
      118
(28 to 532)
 156·3
(38·6 to 458·5)
 406·0
(73·1 to 1709·9)
 211·9
(50·8 to 951·3)
   5·9
(–7·7 to 22·5)
 –3·2
(–16·9 to 10·0)
   0·3
(–6·1 to 8·2)
        Lesotho       113
(58 to 176)
      174
(109 to 289)
      301
(121 to 757)
 200·0
(102·4 to 310·3)
 299·6
(187·9 to 495·0)
 495·4
(199·4 to 1246·4)
   3·8
(−0·8 to 10·8)
   2·2
(−3·3 to 9·7)
   3·0
(−0·4 to 7·8)
        Namibia       102
(69 to 140)
      187
(108 to 280)
        74
(34 to 174)
 190·8
(128·1 to 260·8)
 316·0
(182·6 to 472·6)
 102·4
(47·1 to 240·8)
   5·0
(−1·3 to 10·7)  −8·2
*
(−13·3 to −1·4)
 −3·3
(−5·1 to 1·0)
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Number of maternal deaths Maternal mortality ratio (per 100 000 livebirths) Annualised rate of change in maternal 
mortality ratio (%)
1990 2000 2015 1990 2000 2015 1990–2000 2000–15 1990–2015
        South Africa      1558
(1318 to 1822)
     1611
(1307 to 1901)
     1754
(1396 to 2247)
 153·8
(130·1 to 179·8)
 151·5
(123·0 to 178·8)
 157·9
(125·7 to 202·1)
 −0·2
(−2·6 to 2·1)
   0·3
(−1·3 to 1·8)
   0·1
(−0·9 to 1·2)
        Swaziland         46
(24 to 78)
        48
(30 to 87)
        73
(22 to 216)
 124·7
(65·5 to 212·5)
 140·2
(86·8 to 253·9)
 194·2
(57·6 to 569·7)
   0·9
(−6·2 to 9·4)
   0·6
(−6·0 to 10·3)
   0·9
(−3·4 to 6·4)
        Zimbabwe       826
(612 to 1068)
     1641
(1131 to 2702)
     1 645
(742 to 3616)
 212·6
(157·6 to 274·5)
 400·4
(275·9 to 657·0)
 305·4
(137·8 to 668·5)
   5·8
(2·1 to 11·3)
 −2·3
(−8·4 to 4·1)
   1·1
(−1·8 to 4·7)
    Western sub-Saharan Africa   43 022
(32 030 to 56 
910)
  56 537
(46 496 to 66 
580)
  54 979
(40 856 to 81 
866)
 482·9
(359·7 to 638·4)
 505·8
(416·2 to 595·5)
 362·9
(269·7 to 540·1)
   0·6
(−3·0 to 3·8)
 −2·5
(−4·4 to 0·5)
 −1·2
(−2·9 to 0·8)
              Benin      1223
(845 to 1682)
     1424
(917 to 1903)
     1667
(597 to 4004)
 523·8
(362·2 to 717·3)
 476·4
(307·2 to 635·6)
 429·7
(154·0 to 1025·8)
 −0·9
(−6·7 to 3·8)
 −1·3
(−8·2 to 5·2)
 −1·1
(−5·2 to 3·1)
              Burkina Faso      1639
(1206 to 2067)
     2320
(1526 to 3001)
     2523
(941 to 5007)
 391·5
(288·9 to 493·1)
 431·0
(284·0 to 557·4)
 351·8
(131·3 to 695·8)
   1·0
(−3·7 to 4·8)
 −1·5
(−7·9 to 4·1)
 −0·5
(−4·4 to 2·4)
              Cameroon      2421
(1793 to 2970)
     3659
(2321 to 4852)
     4 137
(1605 to 9156)
 448·5
(335·8 to 550·0)
 556·5
(353·2 to 736·3)
 488·5
(189·6 to 1076·6)
   2·2
(−2·3 to 5·8)
 −1·2
(−7·4 to 4·8)
   0·0
(−3·7 to 3·6)
              Cape Verde         13
(10 to 16)
          9
(6 to 14)
          6
(4 to 8)
   94·5
(74·7 to 116·8)
   72·1
(49·6 to 115·9)
   51·6
(38·7 to 72·1)
 −3·2
(−6·7 to 2·2)
 −2·0
(−6·0 to 1·3)
 −2·5
(−3·9 to −0·9)
              Chad      1451
(973 to 1917)
     2587
(1526 to 3442)
     3466
(1106 to 8614)
 477·1
(320·1 to 629·5)
 605·9
(357·4 to 805·4)
 549·9
(175·8 to 1363·7)
   2·4
(−3·2 to 7·4)
 −1·1
(−8·8 to 5·5)
   0·4
(−4·3 to 4·3)
              Côte d’Ivoire      2504
(1917 to 3074)
     4283
(2950 to 6081)
     4004
(1449 to 7867)
 477·5
(366·0 to 586·3)
 638·7
(441·1 to 904·7)
 477·6
(173·4 to 937·3)
   2·7
(−0·7 to 6·9)
 −2·2
(−8·8 to 3·1)
 −0·2
(−4·1 to 2·9)
              The Gambia       227
(71 to 487)
      257
(168 to 346)
      295
(153 to 539)
 526·0
(166·1 to 1129·6)
 459·6
(301·0 to 616·3)
 354·7
(184·6 to 647·2)
 −1·0
(−8·4 to 8·5)
 −2·1
(−6·7 to 3·1)
 −1·5
(−5·7 to 3·3)
              Ghana      2723
(1542 to 4447)
     3200
(2101 to 4410)
     2615
(1054 to 6187)
 476·2
(270·0 to 777·0)
 489·0
(323·4 to 671·9)
 296·0
(119·4 to 698·9)
   0·5
(−5·7 to 6·7)
 −4·2
(−10·2 to 2·6)
 −2·3
(−6·1 to 2·3)
              Guinea      2061
(1477 to 2571)
     2600
(1919 to 3 
154)
     2779
(1120 to 4875)
 714·0
(512·3 to 890·1)
 690·1
(510·3 to 836·8)
 604·7
(244·2 to 1055·7)
 −0·3
(−3·9 to 3·2)
 −1·0
(−6·9 to 3·4)
 −0·8
(−4·2 to 1·8)
              Guinea-Bissau       244
(55 to 677)
      297
(63 to 857)
      403
(87 to 1492)
 508·6
(114·4 to 1393·1)
 552·7
(117·4 to 1588·7)
 595·4
(128·0 to 2190·7)
   0·4
(−11·1 to 11·4)
   0·2
(−9·8 to 9·2)
   0·0
(−6·4 to 7·3)
              Liberia       718
(396 to 1044)
      787
(500 to 1035)
      950
(417 to 1774)
 753·7
(416·3 to 1095·9)
 664·0
(423·2 to 873·1)
 607·6
(267·0 to 1122·2)
 −1·3
(−6·8 to 5·4)
 −0·9
(−6·3 to 4·5)
 −1·0
(−4·2 to 2·0)
              Mali      2476
(1975 to 2967)
     2792
(2061 to 3363)
     2 631
(1043 to 4600)
 593·6
(473·6 to 709·3)
 519·0
(383·2 to 624·9)
 347·3
(138·0 to 604·5)
 −1·3
(−4·5 to 1·6)
 −2·7
(−8·9 to 1·3)
 −2·1
(−5·9 to 0·3)
              Mauritania       643
(507 to 814)
      622
(319 to 806)
      575
(200 to 1110)
 778·8
(615·7 to 984·0)
 598·3
(307·0 to 775·0)
 428·2
(149·6 to 824·2)
 −2·4
(−8·6 to 0·7)
 −2·5
(−8·4 to 2·9)
 −2·5
(−6·5 to 0·5)
              Niger      1904
(1312 to 2619)
     2795
(1953 to 3731)
     3657
(1617 to 6310)
 434·2
(299·9 to 596·7)
 466·4
(326·0 to 622·4)
 372·0
(165·8 to 639·1)
   0·7
(−3·7 to 5·3)
 −1·5
(−7·1 to 2·8)
 −0·7
(−4·0 to 1·9)
              Nigeria   19 862
(9489 to 33 
627)
  24 972
(16 262 to 33 
862)
  20 321
(11 437 to 43 
168)
 470·7
(225·4 to 796·4)
 472·0
(307·6 to 640·0)
 284·9
(160·4 to 604·6)
   0·5
(−6·9 to 7·9)
 −4·3
(−8·0 to 2·6)
 −2·3
(−5·7 to 2·5)
              São Tomé and 
Príncipe
        10
(7 to 14)
        14
(11 to 19)
        10
(4 to 23)
 230·4
(157·1 to 317·5)
 268·5
(205·3 to 349·6)
 164·2
(65·0 to 367·5)
   1·6
(−2·4 to 6·0)
 −3·8
(−9·5 to 2·3)
 −1·7
(−5·4 to 2·0)
              Senegal      1532
(1097 to 1909)
     1919
(1301 to 2403)
     2577
(942 to 5912)
 467·5
(336·2 to 581·3)
 485·2
(329·4 to 606·7)
 454·3
(166·8 to 1035·3)
   0·4
(−4·4 to 4·7)
 −1·4
(−7·7 to 5·7)
 −0·7
(−4·4 to 3·4)
              Sierra Leone       655
(294 to 1270)
     1076
(775 to 1385)
     1 595
(737 to 2 820)
 369·6
(166·4 to 714·5)
 573·7
(413·8 to 738·8)
 695·7
(321·9 to 1229·1)
   5·2
(−3·2 to 12·4)
   1·2
(−4·4 to 5·7)
   2·8
(−1·3 to 6·3)
              Togo       713
(472 to 912)
      920
(542 to 1257)
      767
(321 to 1 454)
 443·3
(293·6 to 566·8)
 473·8
(279·5 to 643·3)
 298·9
(125·6 to 564·9)
   0·6
(−5·0 to 5·5)
 −3·3
(−9·4 to 2·1)
 −1·7
(−5·1 to 1·4)
    Eastern sub-Saharan Africa   49 401
(42 315 to 57 
626)
  61 389
(52 635 to 71 
472)
  50 443
(36 255 to 70 
958)
 574·9
(493·0 to 670·4)
 582·0
(499·1 to 677·4)
 368·3
(265·6 to 517·0)
   0·1
(−1·6 to 1·7)
 −3·2
(−5·5 to -0·8)
 −1·9
(−3·2 to -0·4)
              Burundi      3110
(1408 to 5853)
     3032
(2062 to 4188)
     1915
(770 to 3 889)
1119·1
(506·9 to 2103·0)
1037·5
(706·6 to 1432·6)
 392·6
(158·4 to 789·8)
 −0·4
(−7·4 to 6·8)  −7·1
*
(−12·9 to -0·5)
 −4·3
(−8·7 to 0·3)
              Comoros       103
(41 to 192)
        97
(72 to 126)
        56
(26 to 107)
 583·6
(232·2 to 1080·5)
 470·4
(352·1 to 611·3)
 213·3
(100·2 to 405·6)
 −1·8
(−8·3 to 7·2)  −5·7
*
(−10·6 to -0·5)
 −4·0
(−7·9 to 0·0)
              Djibouti         86
(35 to 159)
      118
(43 to 283)
      107
(43 to 299)
 378·3
(154·4 to 698·7)
 523·8
(192·3 to 1247·0)
 486·2
(193·8 to 1353·5)
   2·8
(−9·8 to 15·3)
 −0·5
(−9·4 to 9·9)
   0·6
(−4·1 to 6·6)
Lancet. Author manuscript; available in PMC 2017 January 10.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Page 63
Number of maternal deaths Maternal mortality ratio (per 100 000 livebirths) Annualised rate of change in maternal 
mortality ratio (%)
1990 2000 2015 1990 2000 2015 1990–2000 2000–15 1990–2015
              Eritrea      1073
(798 to 1452)
      848
(343 to 1608)
     1319
(345 to 3266)
 815·2
(606·2 to 1101·2)
 645·9
(262·8 to 1224·1)
 752·8
(197·4 to 1859·2)
 −3·1
(−10·8 to 4·3)
   0·5
(−6·5 to 7·0)
 −1·0
(−5·8 to 3·5)
              Ethiopia   18 283
(13 774 to 24 
091)
  21 890
(16 330 to 28 
474)
  13 017
(5497 to 28 
519)
 796·7
(601·0 to 1049·6)
 752·4
(561·5 to 976·0)
 409·8
(173·2 to 892·0)
 −0·6
(−4·4 to 3·0)
 −4·6
(−10·1 to 1·3)
 −2·9
(−6·1 to 0·6)
              Kenya      3668
(2903 to 4614)
     6042
(4842 to 7574)
     5311
(4100 to 6758)
 371·4
(294·0 to 466·0)
 505·0
(404·9 to 632·9)
 338·0
(261·0 to 429·6)
   3·1
(0·9 to 5·3)
 −2·7
(−4·6 to -0·7)
 −0·4
(−1·6 to 0·8)
              Madagascar      1987
(1597 to 2359)
     2763
(1003 to 3733)
     2772
(929 to 6056)
 379·0
(304·8 to 449·9)
 426·5
(155·1 to 575·9)
 333·4
(112·3 to 727·4)
   1·4
(−7·7 to 4·6)
 −2·3
(−8·4 to 5·2)
 −0·9
(−4·9 to 2·7)
              Malawi      2268
(1659 to 2833)
     2939
(1952 to 4527)
     1462
(597 to 2932)
 508·4
(372·3 to 634·8)
 591·5
(392·9 to 908·9)
 219·7
(89·8 to 440·0)
   1·2
(−2·4 to 5·6)  −6·8
*
(−12·5 to -1·7)
 −3·5
(−7·0 to -0·6)
              Mozambique      2187
(1469 to 2984)
     2837
(1622 to 3773)
     3 557
(1 274 to 8 
671)
 347·6
(234·5 to 473·7)
 345·2
(199·4 to 458·2)
 327·2
(117·5 to 797·0)
   0·1
(−6·0 to 4·7)
 −1·0
(−8·0 to 6·2)
 −0·8
(−4·5 to 3·5)
              Rwanda      2142
(1578 to 2961)
     2411
(1861 to 3150)
     1353
(587 to 2878)
 666·9
(491·5 to 920·7)
 772·2
(596·1 to 1007·1)
 373·3
(161·9 to 791·7)
   1·4
(−2·2 to 5·1)
 −5·3
(−11·0 to 0·6)
 −2·5
(−6·2 to 1·0)
              Somalia      2509
(418 to 6 772)
     2899
(489 to 7449)
     3443
(661 to 10 
512)
 830·5
(138·5 to 2193·9)
 811·0
(137·5 to 2077·9)
 731·1
(140·5 to 2218·6)
 −0·3
(−11·8 to 10·4)
 −0·8
(−8·6 to 8·8)
 −0·6
(−6·7 to 6·5)
              South Sudan      1565
(305 to 4258)
     1639
(318 to 4942)
     2868
(589 to 10 
569)
 587·8
(114·7 to 1586·1)
 573·5
(111·5 to 1728·5)
 643·5
(132·4 to 2362·7)
 −0·5
(−11·2 to 10·9)
   0·4
(−9·0 to 10·8)
   0·1
(−6·9 to 7·3)
              Tanzania     6 139
(4654 to 7419)
     7139
(4932 to 9656)
     6974
(2670 to 17 
367)
 544·3
(413·5 to 656·6)
 498·9
(345·0 to 673·7)
 337·8
(129·8 to 841·1)
 −1·0
(−4·8 to 3·0)
 −3·6
(−9·4 to 3·5)
 −2·5
(−5·8 to 1·6)
              Uganda      2923
(2051 to 3820)
     4714
(3426 to 6416)
     4664
(1746 to 10 
115)
 337·4
(237·2 to 440·6)
 408·1
(297·0 to 554·5)
 280·1
(104·9 to 606·4)
   1·8
(−1·5 to 5·3)
 −2·9
(−9·4 to 3·0)
 −1·0
(−4·7 to 2·5)
              Zambia      1334
(1005 to 1682)
     1984
(1432 to 2809)
     1591
(654 to 3231)
 353·9
(267·1 to 446·1)
 424·3
(306·7 to 600·4)
 246·6
(101·7 to 499·3)
   1·7
(−1·6 to 5·6)
 −4·1
(−10·3 to 1·4)
 −1·8
(−5·2 to 1·6)
    Central sub-Saharan Africa   12 058
(7087 to 18 
859)
  14 849
(9631 to 24 
474)
  23 657
(12 760 to 41 
319)
 474·1
(278·8 to 740·5)
 438·9
(284·8 to 721·4)
 497·4
(269·4 to 866·4)
 −0·7
(−5·5 to 4·1)
   0·8
(−3·6 to 4·7)
   0·1
(−2·5 to 2·9)
              Angola      4055
(783 to 10 
270)
     5006
(897 to 14 
417)
     5801
(1242 to 20 
599)
 685·8
(133·2 to 1736·3)
 646·4
(115·8 to 1858·9)
 514·3
(110·7 to 1814·1)
 −1·0
(−12·2 to 10·3)
 −1·7
(−10·9 to 7·6)
 −1·8
(−7·5 to 5·6)
              Central African Republic     1083
(813 to 1 450)
     1496
(460 to 3 269)
     1763
(351 to 4693)
 893·5
(671·0 to 1195·7)
1024·2
(314·9 to 2233·9)
1074·3
(214·7 to 2856·6)
   0·2
(−9·7 to 9·3)
 −0·4
(−8·9 to 8·6)
   0·1
(−5·5 to 4·9)
              Congo
(Brazzaville)
      398
(233 to 650)
      769
(501 to 1118)
      808
(302 to 1707)
 436·0
(255·7 to 709·2)
 638·0
(416·0 to 926·3)
 484·3
(181·6 to 1021·1)
   3·9
(−1·7 to 9·7)
 −2·4
(−8·5 to 4·0)
   0·2
(−3·9 to 4·1)
              Democratic 
Republic of the Congo
     6251
(2952 to 9699)
     7269
(5091 to 9430)
  15 067
(6764 to 26 
513)
 370·7
(176·5 to 572·1)
 318·7
(223·6 to 413·1)
 468·4
(210·5 to 824·1)
 −1·5
(−7·4 to 5·7)
   2·4
(−3·0 to 6·9)
   0·8
(−2·5 to 4·5)
              Equatorial Guinea       161
(29 to 421)
      141
(26 to 439)
      120
(32 to 448)
 913·3
(166·0 to 2384·5)
 676·1
(125·9 to 2098·3)
 409·3
(108·2 to 1516·8)
 −3·6
(−15·9 to 7·3)
 −3·5
(−13·4 to 7·2)
 −4·2
(−9·6 to 3·9)
              Gabon       109
(80 to 149)
      167
(111 to 239)
        98
(43 to 197)
 309·2
(227·1 to 420·7)
 407·9
(274·5 to 584·7)
 191·4
(84·1 to 381·8)
   2·8
(−1·5 to 6·9)  −5·5
*
(−11·2 to 0·6)
 −2·2
(−5·3 to 1·1)
Data in parentheses are 95% UIs. *Shows locations that have met or exceeded the Milennium Development Goal 5 achievement rate of −5·5% 
during any time period.
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Table 2
Average coverage of reproductive health services between including one visit of antenatal 
care (ANC), four ANC visits, in-facility delivery, and skilled birth attendance by MMR 
strata, all years from 1990 to 2015 combined
Antenatal care (1 visit) coverage Antenatal care (4 visits) coverage In-facility delivery Skilled birth attendance
0 to 15   97·7%   95·0%   97·2%   98·5%
15 to 65   94·4%   87·0%   92·3%   95·0%
65 to 75   90·9%   77·5%   82·2%   88·5%
75 to 175   85·9%   65·4%   71·7%   79·6%
175 to 225   84·8%   61·0%   63·6%   69·6%
225 to 500   79·7%   48·4%   49·1%   56·8%
500 and above   74·7%   43·6%   40·0%   47·4%
The coverage values for each aspect of reproductive care show the simple average of all observation for all location-years within the corresponding 
MMR range.
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